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6Abstract 
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of childhood chronic arthritides 
that is associated with chronic uveitis in 20% of cases. Approximately 20-30% of patients 
respond inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs). 
During the last decade new medicinal products, biologic agents, have become available for 
these refractory patients. Among biologic therapies, anti-tumor necrosis factor (anti-TNF) 
agents etanercept, infliximab, and adalimumab are in current use for children.   
We conducted a multicenter study on growth in 71 patients refractory to DMARDs, 
who started etanercept or infliximab treatment before age 15 and had never taken growth 
hormone. Growth was reviewed for 2 years prior to initiation of anti-TNF therapy and for 2 
years after treatment commenced. Records showed that 53 patients (75%) had delayed and 
18 patients (25%) normal or accelerated growth velocity prior to initiation of anti-TNF 
agents. Measured as a change in a height standard deviation score (?HSDS), 53 patients 
with delayed growth demonstrated a significant increase in growth velocity after initiation 
of anti-TNF agents. In them, the mean annual increase in growth velocity was +0.45 [95% 
confidence interval (CI) 0.33 to 0.56, p<0.001] ?HSDS. In 18 patients with normal growth, 
?HSDS was +0.05 (95% CI -0.07 to 0.16, p=0.390). After two years of anti-TNF therapy, 
growth rate in the 53 patients had caught up to that of the 18 patients. The increase in 
growth rate was unrelated to pubertal growth spurt, and also in prepubertal patients growth 
was enhanced. No change was observed in skeletal maturation before and after anti-TNF 
therapy. The strongest predictor of change in growth velocity was growth rate prior to anti-
TNF therapy. The change in inflammatory activity remained a significant predictor even 
after the decrease in glucocorticoids was taken into account. Patients were able to 
significantly reduce their use of glucocorticoids and DMARDs, and at the final visit 52% 
had inactive rheumatic disease.  
In JIA-associated uveitis, we evaluated the impact of two first-line biologic agents, 
etanercept and infliximab, and second-line or third-line anti-TNF agent, adalimumab, on 
anterior chamber (AC) inflammation. Ocular inflammatory activity was graded according 
to the number of AC cells, and improvement in uveitis was measured as reduced number of 
AC cells. In a retrospectively reviewed cohort of 108 refractory JIA patients, uveitis 
occurred in 45 patients (42%), of whom 24 were on etanercept and 21 on infliximab. The 
endpoint ophthalmologic evaluation was at 24 months or at termination of the first biologic 
agent. Of the 45 patients, uveitis improved in 14 (31%), no change was observed in 14 
(31%), and in 17 (38%) uveitis worsened. Uveitis improved more frequently (p=0.047) in 
patients on infliximab than in those on etanercept (43% and 21%, respectively). The 
frequency of annual uveitis flares was higher (p=0.015) in those on etanercept (mean 1.4, 
range 0-3.2) than in those on infliximab (mean 0.7, range 0-2.0). The first phase of uveitis 
occurred during anti-TNF therapy in 5 patients: 4 on etanercept (2.2/100 patient-years) and 
1 on infliximab (1.1/100 patient-years).  
In addition, we reviewed records of 20 patients with JIA-associated uveitis taking 
adalimumab, of whom 17 (85%) had polyarticular JIA and 19 (95%) had previously failed 
etanercept and/or infliximab. The mean duration of adalimumab therapy was 18.7 months. 
Of the 20 patients, in 7 (35%) uveitis improved, in one (5%) worsened, and in 12 (60%) no 
7change occurred. Those with improved uveitis were younger and had shorter disease 
duration. During adalimumab treatment the mean number of annual uveitis flares 
decreased from 1.9 to 1.4. Serious adverse events (AEs) or side-effects were not observed. 
Adalimumab seemed to be effective also in most patients with active arthritis. In arthritis 
symptoms, American College of Rheumatology Pediatric 30% (ACR Pedi30) improvement 
was observed at 3 months in 64% of 14 patients, at 6 months in 57% of 14 patients, at 12 
months in 60% of 10 patients, at 18 months in 83% of 6 patients and at 24 months in 100% 
of 6 patients, respectively.  
In a multicenter follow-up study of JIA patients starting anti-TNF therapy before age 
16, we evaluated long-term drug survival (i.e. continuation rate on drug) during 1999-2007 
and predictors of treatment discontinuation. Of the 209 patients, 105 were taking 
etanercept and 104 infliximab. Drug survival with etanercept vs. infliximab therapy was at 
12 months 83% vs. 80%, at 24 months 68% vs. 68%, at 36 months 64% vs. 53%, and at 48 
months 61% vs. 48%, respectively (p=0.194 in log-rank analysis). The first-line anti-TNF 
agent was discontinued either due to inefficacy (etanercept 28% vs. infliximab 20%, 
p=0.445), AEs (7% vs. 22%, p=0.002), or inactive disease (10% vs. 16%, p=0.068). 
Females, patients with systemic JIA (sJIA), and those taking infliximab as the first therapy 
were at higher risk (assessed as hazard ratios) for treatment discontinuation. One-third of 
patients switched to the second anti-TNF agent, which was discontinued less often than the 
first. During the second-line anti-TNF treatment, 12-month drug survival on etanercept was 
60%, on infliximab 58%, and on adalimumab 66%.  
In conclusion, in the treatment of refractory JIA, TNF? blockers induced enhanced 
growth velocity in patients with growth delay, which was probably due to reduction in 
inflammatory activity rather than a direct effect on growth plates or on skeletal maturation. 
During etanercept or infliximab treatment, ophthalmologic condition of one-third of 
patients with JIA-associated anterior uveitis improved, and infliximab seemed to be more 
effective than etanercept in reducing inflammatory activity of uveitis. Adalimumab was 
beneficial in one-third of JIA patients with chronic anterior uveitis and provided a potential 
treatment option even for patients non-responsive to first-line anti-TNF agents. The four-
year treatment survival on anti-TNF agents was high and comparable between etanercept 
and infliximab, although infliximab was discontinued more often than etanercept due to 
adverse events. In JIA, a switch from the first-line anti-TNF agent to the second-line agent 
appears to be a reasonable therapeutic option. 
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1  INTRODUCTION 
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of disorders of unknown 
etiology and the main connective tissue disease in childhood and adolescence.1 JIA is a 
major cause of functional disability and eye disease in childhood.2, 3 In Scandinavia, the 
approximate incidence of JIA is 15 per 100,000 children, and the prevalence 0.1%.1, 4 In 
40-60% of these individuals, the burden of disease is high and the consequences may be 
life-long.5 Subtypes of JIA have clinically distinct disease courses and long-term outcomes. 
At least juvenile polyarthritis, extended oligoarthritis, and systemic JIA (sJIA) are 
associated with highly active rheumatic inflammation.5
A refractory course of JIA may require long-term use of glucocorticoids, which, 
together with chronic inflammation, are known to induce growth impairment.6
Glucocorticoid treatment has been suggested to induce irreversible damage to growth in 
one-third of JIA patients receiving steroids,7 and in all of those receiving steroids for more 
than one year,6 possibly due to a direct effect on growth plates and other growth-
modulating pathways.  However, in JIA growth has been documented to slow down also 
without preceding steroid treatment.8, 9 Decreased final height has been shown to associate 
with physical disability,10 and decreased growth velocity with disease duration and disease 
flares.9 Pro-inflammatory cytokines have been suggested to impair bone growth,11 but the 
effect of anti-TNF agents on growth is not yet thoroughly known.  
Chronic, nongranulomatous uveitis, involving the anterior part of the uvea, is known to 
be associated with JIA in 5-30% of patients, depending on the subtype. The risk is 
suggested to be highest in antinuclear antibody (ANA)-positive young females with 
oligoarthritis.12-14 The standard therapy for anterior uveitis is topical steroids. If 
inflammation remains active, early immunomodulatory treatment is recommended. 
Methotrexate and cyclosporine A have been suggested to be beneficial in chronic uveitis.14
Regardless of topical and systemic therapy, up to one-third of affected eyes may develop 
impaired vision and one-tenth may become blind.15-17
Conventional therapy for JIA consists of nonsteroidal anti-inflammatory drugs 
(NSAIDs), intra-articular corticosteroids, disease-modifying anti-rheumatic drugs 
(DMARDs), and oral or intravenous (iv) corticosteroids along with nonpharmacologic 
interventions, including physiotherapy and orthoses.18 Approximately 20-30% of all JIA 
patients, mostly those with a highly active polyarthritis, a systemic disease, or a vision-
threatening uveitis may respond inadequately to conventional DMARDs.19-22 During the 
last decade biotechnology has developed new immunomodulatory molecules for treatment 
of these refractory patients. Among the first biologic drugs are anti-TNF agents, which 
have been in clinical use for JIA patients in Finland since 1999. Etanercept is a soluble 
TNF receptor, and infliximab a chimeric monoclonal TNF? antibody. Both have been 
proven effective in treating JIA in randomized controlled trials (RCTs). Since 2003, a 
humanized monoclonal TNF? antibody, adalimumab, effective in treating rheumatoid 
arthritis (RA), has been available for JIA patients. TNF? blockers are highly effective in 
JIA, but their action in childhood uveitis is yet not well known. 
Until recently, placebo-controlled and randomized studies on drug therapy in pediatric 
rheumatology were almost nonexistent. At present, international collaboration has enabled 
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larger patient series, thus providing more reliable data on efficacy of both biologic and 
conventional drug therapies in JIA, but not yet in childhood uveitis. Within the limits of a 
reasonable recruitment phase, the sample sizes in single-center or national studies are 
usually too low to conduct controlled or even observational studies in different 
subpopulations of JIA. 
Our primary focus here was on the long-term safety and efficacy of biologic agents in 
children. Knowing the problems in the research field of pediatric rheumatology mentioned 
above, all JIA patients from the largest Finnish tertiary centers in Helsinki, Heinola, and 
Oulu were included in this study. We reviewed patient charts of all children who had 
received biologic agents since 1999. To enable and facilitate future studies, and as an 
amendment to the Registry of Biologic Treatment in Finland (ROB-FIN), our study group 
founded a children’s register in 2005 with already collected data as the grounding. This 
national ROB-FIN registry was established in 2000 for noncommercial postmarketing 
surveillance of patients with RA, and is comparable to registers in e.g. Sweden, Germany, 
and the UK.
Our interest in growth stemmed from the fact that normal growth reflects the overall 
well-being of a child, and from preliminary clinical observations of growth reconstitution 
in JIA with use of biologic agents. We were also interested in the effect of biologic therapy 
on childhood uveitis, based on a preliminary clinical finding that chronic uveitis seemed to 
improve in a number of patients receiving anti-TNF agents. By 2003, few studies on 
treatment options for chronic uveitis had been published, and only controversial studies or 
case reports were available on biologic treatment in childhood uveitis. Finally, we wanted 
to get an overview of the use of different biologic agents in JIA based on our long-term 
follow-up.
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2  REVIEW OF THE LITERATURE 
2.1 Juvenile idiopathic arthritis (JIA)  
2.1.1 Classification and subtypes of JIA  
Chronic arthritides of childhood are a heterogeneous group of disorders of unknown 
etiology. Their classification has been a source of confusion over the years, with 
inconsistent or overlapping terminology. The term juvenile chronic arthritis (JCA) has 
been used in Europe23 and juvenile rheumatoid arthritis (JRA) in North America.24 JCA 
was proposed by the European League Against Rheumatism (EULAR) and JRA by the 
American College of Rheumatology (ACR). The lack of internationally accepted criteria 
was a major obstacle in identifying homogeneous groups of juvenile arthritis for research 
purposes in immunogenetics, basic science, epidemiology, outcome studies, and 
therapeutic trials. This need led to the formation of the Classification Taskforce of the 
Pediatric Standing Committee of the International League of Associations of 
Rheumatology (ILAR), and the term juvenile idiopathic arthritis (JIA) was introduced.25
ILAR proposed revised classification criteria for JIA in Durban in 1997,26 and a second 
revision in Edmonton in 2001.27 The majority of recent studies and virtually all 
international multicenter trials currently use the ILAR criteria.  
JIA is not a single disease, but an entity including all forms of arthritides of childhood 
that begin before the age of 16 years, persist for more than 6 weeks, and are of unknown 
etiology. Arthritis manifests as a joint swelling or limitation of joint motion with pain or 
tenderness on motion. Seven disease categories have been recognized on the basis of 
features present or absent (inclusion and exclusion criteria) during the first 6 months of 
illness (Table 1). Those fulfilling criteria in no category or in more than one category are 
defined as undifferentiated arthritis.27 Apart from classification criteria, a few descriptors 
are usually presented to gain further information about the outcome and the clinical 
features of each patient. Descriptors, such as presence of ANA, acute or chronic anterior 
uveitis, age at onset, and location of arthritis, are of clinical interest and may in the future 
enable reclassification of JIA. However, scientific evidence of the value of these 
descriptors in classification criteria is still insufficient.  
A relationship exists between the subtypes of juvenile arthritides and rheumatic 
diseases of adulthood.  Juvenile seropositive polyarthritis is thought to be early-onset RA,28
29
 and sJIA resembles adult-onset Still’s disease.30, 31 Enthesitis related arthritis (ERA), 
affecting the entheses and axial skeleton in addition to peripheral joints, belongs to the 
group of spondyloarthropathies. The term includes children with juvenile ankylosing 
spondylitis (who meet the criteria for adult ankylosing spondylitis) and most patients with 
undifferentiated spondyloarthritides. In a Mexican study of children with ERA (formerly 
called seronegative enthesopathy and arthropathy), progression to definite juvenile 
ankylosing spondylitis occurred in 75% of patients.32
15
Table 1 JIA subtypes 1-6 with inclusion and exclusion criteria, excluding undifferentiated 
arthritis (no. 7), based on the second revision of ILAR criteria [27]. 
Category Subcategory Inclusion criteria  Exclusion criteria 
1.Oligoarthritis  Arthritis in 1-4 joints during the 1st 6mo 
 Persistent 1a. affects < 5 joints throughout disease 
 Extended 1b. affects ? 5 joints after the 1st 6 mo 
Psoriasis or 6c; 5b 
with 5c; 5e or these 
disorders in a 
patient; 3a; sJIA 
Polyarthritis   Arthritis in ?5 joints during the 1st 6 mo 
 2. Seronegative 2a. RF-negative 
 3. Seropositive 3a. RF-positive at least 2 times at least 
3 mo apart during the 1st 6 mo 
Psoriasis or 6c; 5b 
with 5c; 5e or these 
disorders in a 
patient; sJIA 
4. Systemic 
arthritis   
Arthritis in ? 1 joints with or prior to 2-
week fever?and ? 1 of following: 
4a. Erythematous nonfixed rash 
4b. Generalized lymph node 
enlargement 
4c. Hepato- and/or splenomegaly 
4d. Serositis²
Psoriasis or 6c; 5b 
with 5c; 5e or these 




Arthritis and enthesitis³, or arthritis or 
enthesitis with ? 2 of following: 
5a. Present or history of SI tenderness 
and/or inflammatory lumbosacral pain 
5b. Presence of HLA-B27  
5c. Onset of arthritis in males aged >6y 
5d. Acute symptomatic anterior uveitis 
5e. History of AS, ERA, sacroiliitis 
with IBD, Reiter’s syndrome, or acute 
anterior uveitis in 1st degree relative 
Psoriasis or 6c; 3a; 
sJIA 
6. Psoriatic 
arthritis   
Arthritis and psoriasis, or arthritis and  
? 2 of following: 
6a. Dactylitis 
6b. Nail pitting or onycholysis 
6c. Psoriasis in 1st degree relative  
5b with 5c; 5e or 
these disorders in a 
patient; 3a; sJIA 
? fever: daily and quotidian (rises to ? 39°C daily and returns to ? 37°C between fever peaks) ? 3 days 
² serositis: pericarditis and/or pleuritis and/or peritonitis 
³ enthesitis: tenderness at the insertion of a tendon, ligament, joint capsule, or fascia to bone   
See “Abbreviations” for further definitions. AS ankylosing spondylitis, ERA enthesitis related arthritis, IBD 
inflammatory bowel disease, mo months, SI sacroiliac joint, sJIA systemic JIA, y years 
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2.1.2 Epidemiology of JIA 
JIA is the most common rheumatic disease in childhood. The exact frequency of JIA is 
unknown, but it has been described in all geographic areas. A comparison of published 
data on the occurrence of JIA is challenging due to inconsistent disease definitions, 
underreporting, and studies involving both individual centers and pooled data from 
regional populations.  
In a Caucasian population of subjects less than 16 years of age, the reported prevalence
of JIA from studies published during the last two decades ranges from 20 to 200 per 
100,000 (Europe, USA, Canada),1 and in Scandinavian studies from 86 to 148 per 
100,000.33, 34 Based on investigations of Gäre et al.33 and Moe et al.34, the estimated 
prevalence in Scandinavia is approximately 1 per 1000 children. The incidence of JCA or 
JIA varies between 2 and 23 per 100,000,1 but is reported in most studies between 8 and 15 
per 100,000.4, 33, 35-37 In the Finnish population, the reported incidence was 13.8-15.1 in 
1980-1990,38 18.2 in 1982-1983,39 19.5 in 1995,40 and 21 per 100,000 in 1997-1999.4
The age at disease onset depends greatly on the subtype. Especially in girls, the 
incidence is highest between 1 and 3 years of age.4, 33 Approximately twice as many girls 
as boys are affected, although this proportion varies in different subtypes. Oligoarthritis is 
the most common subtype, comprising more than half of the cases, while approximately 
one-quarter of patients have polyarthritis, and in Scandinavia, less than one-tenth have 
sJIA.4, 33 Ravelli et al.41 suggested ANA positivity to be considered as a modifier for 
diagnostic criteria. This proposal was based on a finding that ANA positive patients with 
similar characteristics in terms of age at onset, gender, and frequency of symmetric arthritis 
and uveitis now belong in several different JIA categories and subcategories.41 The 
proportion of patients in each category has been of interest in recent publications (Table 
2).4, 42-45 In a recent population-based Scandinavian study,4 63% of patients  were female 
and 34% male. Of females, 42% were ANA-positive and of males 34%. Oligoarticular 
disease was observed in 66%, polyarticular disease in 23%, psoriatic arthritis in 3%, and 
sJIA in 4%. Only 3% of patients were rheumatoid factor (RF)-positive, 4% had ERA, and 
24% had unclassified arthritis.4
Globally, the proportion of oligoarthritis is 27-56%, being more common in females. In 
persistent oligoarthritis, peak incidence occurs at 1-2 years, and ANA may be present in up 
to 80% of cases.46, 47 Up to 50% of those with oligoarticular onset may eventually develop 
into extended disease.48 Polyarthritis occurs in about 30% of patients, with a female 
predominance, and onset of disease is observed throughout childhood, with a peak at 1-3 
years. RF is present in less than 5% of subjects, and is more common in adolescent girls.46, 
47
 Systemic arthritis affects both sexes equally; onset is seen throughout childhood, and 
occurs in 4-17% of JIA patients.46, 47 Of JIA patients, 3-16% belong to a category of 
ERA47, 49 in which also those with juvenile spondylarthropathy (JSPA) are classified. ERA 
is strongly associated with the presence of human leukocyte antigen B27 (HLA B27). 
Approximately 2-11% of patients belong to the category of juvenile psoriatic arthritis 
(PsA).33, 37, 47
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Table 2 Proportion (%) of patients  in each category and subcategory of JIA in recent 
publications with an epidemiologic focus and mainly population-based data. 
 Oligoarthritis Polyarthritis sJIA ERA PsA 
Author and year        (n) persistent extended RF-neg RF-pos    
Minden 2002        (215)? 40 13 1 14 15 1 
Thomson 2002      (421)? 30 15 20 7 14 7 7 
Berntson 2003      (315)? 41 5 19 2 4 4 3 
Merino 2005         (125)? 43 20 2 14 14 1 
Pruunsild 2007     (160)? 44 11 21 4 4 7 3 
See “Abbreviations” for further definitions. PsA psoriatic arthritis 
?Hospital-based study, regional population (long-term outcome; disease onset in 1978-1988) in Berlin  
?JIA cohort of Caucasian origin in multicenter study (17 centers) for HLA associations in the UK 
?Multicenter study, regional population from Scandinavia (1997-1998), 24% had unclassified arthritis 
?Hospital-based study, regional cohort in Madrid  
?Hospital- and population based study in Estonia (1999-2001) 
2.1.3 Long-term outcome of JIA 
In the evaluation of outcome, the focus has traditionally been on physical and functional 
measures, i.e. disease activity, joint damage, and physical disability. Steinbrocker classes 
are adult-oriented and rough, but have been used as a measure of functional status in 
patients with JIA for almost 6 decades.50 The classes range from I (complete functional 
capacity with ability to carry on usual duties without handicaps) to IV (largely or wholly 
incapacitated with patient bedridden or confined to wheelchair, permitting little or no self-
care). A self-administered Health Assessment Questionnaire (HAQ) has been validated to 
evaluate the physical function in RA,51 and a self- or parent-administered Childhood HAQ 
(CHAQ) is a comparable measure for juvenile patients.52 Both the currently used HAQ and 
CHAQ cover 8 activity areas; dressing and grooming, rising, eating, walking, hygiene, 
reaching, gripping, and other activities; providing an overall disability score within range 
0-3. Compared to HAQ, in CHAQ for each functional area several questions has been 
added, including at least 1 question relevant to children of all ages.52 In long-term outcome 
studies the evaluation with CHAQ is increasing, although not wide yet. Other measures 
assessing long-term damage in JIA are available but rarely used, such as modified 
Sharp/van der Hejde Score53 or Poznanskis score,54, 55 in which the radiographic damage is 
assessed either by carpo-metacarpal ratio or by carpal length, respectively. A clinical 
measure for articular and extraarticular damage, a Juvenile Arthritis Damage Index 
(JADI),56 has been published in 2005 and is currently in experimental use. Outcome 
domains for JIA can also include psychosocial well-being, pain perception, socioeconomic 
status, osteoporosis, growth, surgical procedures, and ocular sequelae.   
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In the past, 80% of children have been suggested to reach adulthood in clinical 
remission. This optimistic view has been challenged by a number of recent studies.5 The 
proportion of JIA patients achieving remission was 40-60% during a follow-up period of 
up to 28 years.2, 10, 42, 57-62 Approximately 10% of these patients had severe functional 
impairment, measured by Steinbrockers’ functional class III or IV.2, 10, 42, 59, 63-65
Subtype-specific outcome 
The outcome seems to be associated with the subtype of JIA, being the best in persistent 
oligoarthritis and worst in RF-positive polyarthritis.47 However, in persistent oligoarthritis, 
chronic uveitis or unremitting arthritis causes increased morbidity.47, 48 In extended 
oligoarthritis, the morbidity resembles that of polyarthritis, or is even worse (Table 3).63
Systemic symptoms in sJIA are often self-limited, but in up to half of patients the disease 
may be long-lasting and arthritis destructive.10, 66 Foster et al.67 observed that more patients 
with polyarthritis, sJIA, or psoriatic arthritis had physical disabilities than patients in other 
JIA categories. Bowyer et al.68 documented that after 5 years from disease onset more than 
25% of patients with polyarthritis and nearly a half with sJIA had functional limitations, 
and altogether two-thirds had radiographically evident joint space damage.68
In a Norwegian study, half of the 133 JRA patients were in remission after a median of 
15 years from disease onset. The remission rate was 35% in extended oligoarthritis, 15% in 
seropositive polyarthritis, 46% in seronegative polyarthritis, and 76% in sJIA.61 In long-
term follow-up studies, the proportion of patients in clinical remission has been 33-80% in 
sJIA, 0-25% in seropositive polyarthritis, 23-46% in seronegative polyarthritis, 7-35% in 
extended oligoarthritis, and 42-73% in persistent oligoarthritis.2, 10, 42, 59, 61, 63, 64, 69 The 
remission rate has been demonstrated to increase during the first 5 years from disease 
onset, reach its peak at years 5-10 and then slowly decline.60 Altogether 91% of remissions 
occur before the 16th birthday.2 Recently, the time spent in active and inactive disease was 
evaluated. The majority of patients with extended oligoarthritis, polyarthritis, and sJIA 
spent nearly two-thirds of their time with active disease. Although 44% achieved clinical 
remission off medication, it lasted less than 2 years in the majority and 5 years in only 6% 
of patients.70
A review of the results in a regional cohort with JIA onset 2-3 decades ago in Berlin 
provides a good insight into the possible long-term physical consequences of JIA.42 In 
1998-1999, half of the patients still had active disease and/or long-term complications of 
rheumatic disease. At a 17-year follow-up, the physical status and complications of the 
cohort were as follows: limitation of motion in more than 4 affected joints in 12-100% 
depending on subtype, leg length disturbances in 25%, uveitis and/or visual impairment in 
14%, micrognathia in 10%, cardiac involvement due to rheumatic disease in 5%, hip or 
knee prostheses in 2% (8 prostheses in 5 patients), amyloidosis with renal insufficiency in 
1%, and growth retardation (unspecified). In addition, 45% had undergone surgery due to 
complications of JIA.42
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Table 3 Subtype-specific long-term outcome and disease activity in severe JIA. The 
proportion of patients in JIA categories is presented, when available. 
Subtypes (% of each study cohort) Author and year (n)  Disease 
duration 
(years)? Poly RF+/- Ext-oligo sJIA ERA?
Active disease 
(%) 
P RF+/-,Eo,S,E  
Steinbrockers’ 
class III-IV? (%) 
P RF+/-, Eo,S,E 
David 1994        (43) 20 30 / 21 16 32 - 85/33, 71, 14, - 15/12, 43, 0, - 
Zak 2000           (65) 26 26 34 8 - 47, 50, 20, - 11 
Lomater 2000    (80) 11 - - 100 - 40 29 
Fantini 2002    (530) 11 4 / 12 15 13 10 100/76,-, 69, 71 - 
Minden 2002   (215) 17 1 / 13 12 14 15 100/70, 88,45,56 12 
Oen 2002         (392) 11 10 / 20 11 12 - 100/76, -, 64, - 5/3, -, 7, - 
Packham 2002 (246) 28 15 / 17 22 21 13 43  41/38, 36, 65, 6 
Flatø 2003       (268) 15 13 / 23 21 11 - 85/54, 65 , 24 , - - 
Foster 2003       (82) 21 15 / 24 16 15 12 P: 83/65, all: 39 - 
Arkela-K 2005 (123) 16 3 / 19 12 1 - 75/57, 93, 50, - - 
Flatø 2006         (55) 23 - - - 100 56  - 
P RF+/- or poly RF+/-  seropositive/seronegative polyarthritis, Ext-oligo or Eo extended oligoarthritis, S or sJIA systemic 
arthritis, E or ERA enthesitis related arthritis, - no data  
?Mean or median, ?In earlier studies juvenile SPA, ?Severe disability in those with P/Eo/S/E (OR whole cohort) 
A limited number of studies describe the outcome in ERA. In a recent case-control study,49
patients with ERA had poorer physical health and more bodily pain than those with 
oligoarthritis or polyarthritis or controls in the general population. Among ERA patients 
with a median disease duration of 23 years, sacroiliitis was observed in 35% and reduced 
spinal flexion in 75%.49 Persistent disease is reported to most often be seen in patients with 
polyarthritis and extended oligoarthritis59or ERA.49
Early predictors of unfavorable outcome 
A number of predictive factors have been suggested for poor outcome, measured by 
physical disability, radiographic damage, and/or unremitting disease. These include 
articular severity score;71 prolonged active disease, late admission, and late start of 
DMARDs;65 female gender and positive RF;61, 64 HLA-B27 present and onset age of more 
than 6 years;72 HLA-B27;61, 73 HLA-B27, DRB1*01, DRB1*08, polyarticular disease, 
symmetrical arthritis, young age at onset, hip involvement, and long duration of elevated 
erythrocyte sedimentation rate (ESR);61 young age at onset and greater restricted joint 
count.74 For sJIA, male gender75 and persistent systemic features with thrombocytopenia at 
6 months from onset are predictors for physical disability.76 The latter is suggested to also 
be a predictor of articular damage,77, 78 as is also the presence of pulmonary or cardiac 
serositis within 6 months from onset.78 However, at diagnosis none of these measures can 
accurately predict which children will have unfavorable outcome and require the most 
aggressive treatment. 
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Disturbances in growth and pubertal development 
One of the permanent complications of JIA is growth impairment and reduced final height, 
which is seen especially in polyarthritis and sJIA.7, 9, 42, 79 Physical disability may be 
associated with decreased final height.10 Both active inflammation and concomitant intake 
of glucocorticoids can cause a reduction in linear growth.80, 81 Growth has been reported, 
however, to slow down also without previous steroid treatment.8, 9 Immobilization, direct 
damage to the joints involved, and poor nutrition have also an impact on growth. 
Normal growth requires the presence of normal thyroid function, and the pulsatile 
secretion of growth hormone (GH) with GH-dependant insulin-like growth factor-1 (IGF-
1). Both normal and impaired spontaneous or stimulated GH secretion has been reported in 
children with JIA and severe growth retardation.82-84 It has been suggested that the 
underlying mechanism of growth impairment in JIA is not classical GH deficiency, but GH 
insensitivity.84
Improvement of growth rate and even achievement of target height have been 
documented in several patients receiving GH,83, 85 but the results in different series are 
inconsistent, and growth is not restored in all patients. In a recent RCT, significantly more 
of the 13 patients treated with GH were reported to reach expected final height than the 18 
subjects in the control group. A significant difference in height outcome existed, however, 
only in patients with moderate disease activity, but not in those with high disease activity.85
In a retrospective study of 37 patients with polyarthritis or sJIA, significant negative 
relations were found between disease duration and growth velocity, and disease flares and 
growth velocity. Of those whose growth decreased ? 1 height Z-scores, none entering 
remission had catch-up growth.9 In another study of 22 sJIA patients, 30% had no catch-up 
growth after prednisolone discontinuation. In all 22, the mean final height was -2.0 ± 1.8 
height standard deviation scores (HSDS), which was below target height in 87%.7 Wang et 
al.6 suggested that irreversible growth impairment occurs, once the glucocorticoid 
treatment has lasted for more than a year.  
It is commonly assumed that a chronic disease in childhood delays puberty. Delayed 
bone age can reflect a delayed maturation process also in prepubertal children. Studies 
concerning onset of puberty or skeletal maturation in JIA are few. In the timing of 
menarche, a significant difference was observed between 68 JRA patients and 46 controls. 
Menarche was delayed most in those with polyarthritis. Duration of disease was a weak 
predictor for the timing of menarche.86 In an Italian study, 83 JCA patients with or without 
glucocorticoid treatment, all but especially those on steroids had delayed timing of 
menarche compared with their mothers and healthy girls.87 In contrast, a Swedish study on 
reproduction ability of young adults reported that menarche occurred at a median age of 13 
years both in 126 females with JCA and in 117 healthy controls.88
Local inflammation and production of growth factors may cause overgrowth of the 
affected limb or a premature fusion of the involved epiphyses, resulting in diminished 
length. Arthritis in the lower limb may thus result in discrepancy of leg lengths. 
Micrognathia and retrognathia are examples of localized growth disturbances in 
temporomandibular joints. Arthritis in wrists or elbows may advance bone age.46, 47
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A failure to develop adequate bone mineralization has been common in children with 
JIA and is characterized by impaired bone formation and a failure to undergo a normal 
increase in bone mass during puberty. Thus, the potential of JIA patients to achieve an 
adequate peak skeletal mass may be markedly decreased.89 The onset of accelerated 
skeletal maturation with puberty is a critical period of potential intervention in JIA. 
Therapeutic interventions later during adolescence are less promising in reversing 
inadequate bone mineralization.90 In a recent Finnish study on bone health in a JIA cohort 
of 62 patients, bone age was delayed by ? 1 year in 24% and advanced by ? 1 year in 
19%.91 Areal bone mineral density (aBMD) Z-scores for the lumbar spine were only 
slightly below the population mean, and the occurrence of asymptomatic vertebral 
fractures was 10%. The frequency of osteopenia in this cohort was markedly lower91 than 
in patient series with disease onset before the wider use of immunosuppressive and 
biologic agents,92 reflecting the improved treatment regimens.   
2.1.4 Assessment of disease activity and treatment response 
In adult RA, ACR criteria has been produced to measure treatment response,93 ACR20, 
ACR50, and ACR70 showing 20%, 50% and 70% improvement in core sets of criteria, 
respectively.94, 95 To achieve ACR20, improvement of ? 20% in both swollen and tender 
joint counts is required, as well as ? 20% improvement in 3 of following 5: patient pain 
assessment, patient global assessment, physician global assessment, patient self-assessed 
disability (e.g. HAQ), and  acute phase reactant (ESR or CRP).94 Additionally, EULAR has 
produced a measure for disease activity, a Disease Activity Score (DAS), which was 
further modified to the DAS in 28 joints (DAS28).96, 97 One of a few comparable equations 
in calculating DAS28, where TEN28 is equal to 28-joint count for tender joints, SW28 for 
swollen joints, and GeH to general health assessed by visual analog scale (VAS), is as 
follows: 96, 97
DAS28 = 0.56 x ?TEN28 + 0.28 x ?SW28 + 0.70 x lnESR + 0.014 x GeH 
Substantial differences exist between ACR criteria and DAS; the former were developed to 
distinguish differences between active treatment and placebo, and the latter between high 
and low disease activity. ACR criteria define improvement on the basis of relative 
variation, whereas DAS includes absolute variation and the level achieved. ACR criteria 
include two outcome categories (responder/ nonresponder), and DAS three (good, 
moderate, absent). In clinical trials, ACR criteria and DAS perform similarly in identifying 
responders.98 Juvenile DAS, JADAS, is currently being developed and validated.99
American College of Rheumatology (ACR) Pediatric criteria 
In 1997, Giannini et al.100 defined preliminary core sets of criteria and a definition of 
improvement in JIA, termed as the ACR pediatric 30% response criteria (ACR Pedi30). 
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This definition is comparable with the ACR criteria in adult RA, but no measure 
comparable with DAS has yet been validated for children.  
ACR Pedi30 includes improvement of at least 30% from baseline in 3/6 core set 
variables, whereas in ACR Pedi50 the improvement must be at least 50%, and in ACR 
Pedi70 at least 70%. The 6 core set variables are as follows: number of active joints, 
number of joints with limitation of motion and pain or tenderness, physician’s assessment 
of disease activity, parent’s assessment of the well-being of the child, a validated measure 
of physical function, and a laboratory measure of inflammation. Most often, physicians and 
parents use a 100-mm VAS to measure disease activity and child’s well-being, 
respectively. Physical function is evaluated by CHAQ, and the level of inflammation by 
ESR or C-reactive protein (CRP). To fulfill the definition of improvement, no more than 1 
of the remaining variables can worsen by more than 30%.100 A recent study reported a low 
correlation between the tender joint count and CHAQ early in the disease course, but a 
high correlation in longstanding disease.101 A minimum of 40% worsening in a minimum 
of 2/6 core set variables, with no more than 1 variable improving by ? 30%, has been 
suggested as a preliminary definition of disease flare.102
ACR Pediatric measures primarily the relative efficacy in the context of clinical trials 
and is less useful in quantifying or assessing longitudinal response or describing disease 
activity at a specific moment. The relation between the ACR and EULAR criteria in JIA 
has recently been examined in a cohort of 75 children with polyarticular JIA receiving 
methotrexate (MTX) or TNF? inhibitors. The highest concordance was observed between 
the DAS and the ACR Pedi30, the lowest between the DAS28 and the ACR20. The 
researchers suggested that the ACR Pedi30 could be used in adult patients affected with 
JIA, and that the original DAS was an alternative to the ACR Pedi30 in children and 
adolescents with JIA.103 Future studies will determine whether DAS is responsive enough 
to be used as continuous measure of disease activity in children.  
The outcome measures mentioned above do not include any specific criteria for 
evaluating the potential activity of uveitis, instead focusing on arthritis.  
Inactive disease and remission 
The primary goal of the management of JIA is the achievement and maintenance of 
remission, defined as the absence of all active rheumatic disease, i.e. arthritis and systemic 
features, including uveitis. The preliminary criteria of inactive disease for JIA is defined as 
follows: no active synovitis; no fever, rash, serositis, splenomegaly, or generalized 
lymphadenopathy attributable to JIA; no active uveitis; normal ESR and/or CRP; and 
physician’s VAS indicating no active disease.104 No consensus has been reached in the 
definition of inactive uveitis, in which the required anterior chamber cell activity ranges 
from grade 0 to 1+.104
Clinical remission on medication is defined as 6 continuous months of inactive disease 
on medication. Clinical remission off medication is defined as 12 continuous months of 
inactive disease off all anti-arthritis and anti-uveitis medications.104 These definitions 
provide a first important step towards standardization of reporting of remission rates, 
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which can also be useful as the outcome measures of therapeutic trials. However, they have 
not been prospectively validated. An interesting investigation of adult RA reported that 
96% of patients, classified as being in clinical remission based on clinical examination by 
consultant rheumatologists, had evidence of synovitis in gadolinium-enhanced magnetic 
resonance imaging (MRI).105
2.2 JIA-associated uveitis 
2.2.1 Inflammation of the uvea 
Uveitis is an inflammation of the uveal tract of the eye, composed of the iris, ciliary body, 
and choroid (Figure 1). As early as in 1987, the International Uveitis Study Group (IUSG) 
recommended the subdivision of uveitis by affected structure.106 In 2005, the international 
consensus workshop of the Standardization of Uveitis Nomenclature (SUN) endorsed and 
completed this classification.
Anterior uveitis (including iritis, iridocyclitis, and anterior cyclitis) refers to an 
inflammation of the anterior chamber (AC). Intermediate uveitis (including pars planitis, 
posterior cyclitis, and hyalitis) involves the vitreous, and posterior uveitis (including focal, 
multifocal, or diffuse choroiditis, chorioretinitis, retinochoroiditis, retinitis, and 
neuroretinitis) the retina or choroid. The term panuveitis describes a uveitis that involves 
the AC, vitreous, and the retina or choroid. The primary site of inflammation is determined 
clinically.106, 107
The onset of uveitis can be described as sudden or insidious. The duration can be either 
limited (? 3 months) or persistent. The course can be chronic (persistent uveitis with 
relapse in less than 3 months after discontinuing treatment), recurrent (repeated episodes 
separated by periods of inactivity without treatment ? 3 months in duration), or acute
(sudden onset and limited duration).107
The inflammation is marked by leukocytic infiltration and an increase in vascular 
permeability, which an ophthalmologist can visualize directly using a slit lamp.108 In the 
normally clear media of the AC and vitreous cavity, during inflammation leukocytes can 
be identified and quantified, and the extravasated protein in the anterior eye is visible as a 
haze, referred to as “aqueous flare”. The anatomic location of uveitis determines the 
clinical features. In anterior uveitis, photophobia, tearing, redness around the iris, and 
blurred vision are common. The ophthalmologic examination may reveal ciliary injection 
(congestion of vessels at the corneoscleral junction), keratic precipitates (collections of 
leukocytes on the internal surface of the cornea), aqueous cells and flare, anterior 
synechiae (iridocorneal adhesions), posterior synechiae, and/or iris nodules.108 Anterior 
JIA- associated uveitis has an unusual presentation, most often being asymptomatic. It is 
therefore detected by routine screening only. 
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Figure 1 Diagram of the human eye. The uveal tract is composed of the iris, the ciliary body, 
and the choroid. A typical JIA-associated uveitis is chronic, with the inflammation 
located in the anterior chamber. Reprinted; originally published in 1918 in Gray’s 
Anatomy of the Human Body; now freely licensed in Wikimedia Commons. 
2.2.2 Epidemiology of JIA-associated uveitis 
A systemic inflammatory disease, most commonly an HLA-B27 associated 
spondylarthropathy, sarcoidosis, and, in children, JIA, is associated with uveitis in half of 
all patients referred to tertiary care facilities.109 Population-based studies in Caucasian 
patients have suggested that the overall annual incidence of uveitis is 11-23 per 
100.000,110-112 and the estimated prevalence is 75-200 per 100.000.111, 113 The prevalence 
seems to be higher in the developing world,113, 114 where the infectious causes of uveitis, 
e.g. tuberculosis and toxoplasmosis, are more frequent, and asymptomatic uveitis is 
virtually never screened. Compared with adults, uveitis is considerably less common in 
children, being observed in approximately 5% of all uveitis cases.115, 116
Due to the rarity of childhood uveitis, population-based surveys are few, and with small 
patient series of limited value. In a recent Finnish study, the incidence and prevalence per 
100.000 for anterior uveitis was 4.0 and 25, and for JIA-associated uveitis 1.1 and 13.9, 
respectively. Of the 55 patients with childhood uveitis, 91% had anterior and 82% JIA-
associated or idiopathic uveitis.116 Of note, the term idiopathic uveitis is presumed to 
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represent a local autoimmune process of the eye. In a British study, the incidence of uveitis 
in patients less than 16 years was 4.9 per 100.000.117 In the whole cohort of 249 patients 
aged under 20 years at onset, 54% had chronic anterior, 16% acute anterior, and 30% 
posterior uveitis, the etiology of the latter being toxoplasmosis or idiopathic. In this cohort, 
uveitis was idiopathic in 44% of patients and JIA-associated in 47%.117
Noninfectious uveitis is associated with JIA in approximately 20% of patients.10, 61, 118-
120
 In most cases, uveitis is asymptomatic anterior chronic iritis or iridocyclitis with 
bilateral involvement.17, 118 In one-tenth of patients, uveitis is detected before arthritis.12, 17, 
121
 The risk for uveitis has been suggested to be especially high in ANA-positive females 
with oligoarthritis and young age at onset.12, 13, 17, 121 However, in a long-term follow-up, 
Guillaume et al.48 found no higher risk for uveitis in those with than without ANA, or in 
those with extended vs. persistent oligoarthritis. 
In patients with oligoarthritis, uveitis is observed in 16-47%, and the risk has been 
reported to be higher in persistent12, 42, 121 or extended disease,17 or both10 compared with 
other subtypes. Uveitis occurs in 5-24% of patients with seronegative polyarthritis10, 42, 120, 
121
 and in 2-23% of those with PsA,10, 121 but is uncommon in patients with seropositive 
polyarthritis and sJIA.10, 12, 17 Uveitis may also be acute, with a much better prognosis, 
especially with HLA-B27 or ERA-associated disease, in which 8-28% of the patients are 
affected.3, 10, 13, 14, 42, 121 Patients with remission in arthritis may have a highly active uveitis, 
and most often uveitis and arthritis seem to follow different courses,120 although some 
controversy exists.122
2.2.3 Complications and visual outcome  
Unless uveitis is detected and treated early, patients are at risk of developing severe visual 
impairment, visual loss, and other sequelae.12, 123, 124 In 1988, in a study of 315 JCA 
patients with uveitis, approximately one-fourth were reported to have an excellent visual 
prognosis, one-half a more severe, but still controllable uveitis with topical medication, and 
one-fourth a poor visual prognosis.118 During the last decade, the use of systemic 
medication has become more frequent in patients with uveitis. In 2007, one-half were 
reported to require immunosuppressives.121 Even though a decreased incidence of 
complications has been observed, the rate in the latest publications is still high; 49-71%.17, 
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 Complications include cataract in 22-71%, glaucoma in 15-32%, band keratopathy in 
14-66%, posterior synechiae in 22-28%, macular edema in 3-6%, and ocular hypotony in 
4-19% of patients.10, 17, 121, 123, 125 The highest complication rates have been reported in 
those with seronegative polyarthritis (67%) or extended (58%) or persistent (54%) 
oligoarthritis.10, 17 Abnormal vision is associated with synechiae or cataract,121 and worse 
visual prognosis with longer delay before referral to a specialist.124
The visual outcome is usually reported as the best-corrected visual acuity (BCVA). 
Visual loss is defined as BCVA ? 0.1 (equals to ? 20/200), visual impairment as BCVA 
0.2-0.4 (equals to 20/100 - 20/50), and good visual acuity as ? 0.5 (equals to ? 20/40).107
The reported rate of visual loss has decreased during the last two decades, but is still 
considerably high. Impaired vision in 30-46% of patients in at least one eye and visual loss 
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in 12-26% has been documented.17, 117, 120, 123, 125 Short-term reports have been published in 
Canada and Finland, where visual impairment occurred in 4% and 3%, visual loss in 9% 
and 0% of JIA patients, and an overall complication rate of 37% and 24%, respectively.119, 
121
 The low rate may be due to better screening, earlier and more effective treatment, 
and/or selection bias.
Long-term outcome studies evaluating the chronicity of JIA-associated uveitis are few. 
In such studies with a follow-up of more than a decade, one observation is the development 
of uveitis in 30% of those aged over 16 years.126 Moreover, chronic inflammation of the 
eye was active in 42% and 63% after a mean duration of 16 and 21 years, respectively.15,
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 At the 16- and 21-year follow-ups, ocular complications have been observed in 80% 
and 100% of patients, respectively.15, 42 BCVA was impaired in 40% of the eyes, poor 
(20/150) in 20% and lost (no light perception) in 10%.15 Severe uveitis at initial ocular 
examination has been shown to correlate with worse prognosis, and systemic steroids with 
cataract formation.127
2.2.4 Assessment of activity of uveitis  
Activity of AC inflammation of uveitis is based on the quantity of cells in the AC on 
standard slit-lamp examination. AC inflammation is graded from 0 to 4 (grade /AC cells in 
field): 0 /<1, 0.5+ /1-5, 1+ /6-15, 2+ /16-25, 3+ /26-50, 4+ />50. An improved activity of 
uveitis is defined as either a 2-step decrease in the level of inflammation or a decrease to 
inactive level (grade 0), and a worsening of inflammation as either a 2-step increase in the 
level of inflammation or an increase to the maximum grade 4+. In healthy individuals, a 
rare cell (but < 1 cell per field), has been demonstrated. Inactive anterior uveitis is defined 
as rare or no cells, and the presence of 1 cell in every field is indicative of grade +0.5 
(“trace cells”) and should not be considered inactive uveitis. Remission is defined as 
inactive disease for ? 3 months after discontinuing all treatments for eye disease.107
The presence or absence of hypopyon is recorded separately. The presence of vitreous 
cells is an important clinical feature, but no consensus has thus far been reached on a 
grading system. Macular edema is reported as present or absent, as determined clinically. 
The term glaucoma is not considered synonymous with elevated intraocular pressure, but 
should be reserved for situations where either glaucomatous disk damage is observed or 
visual field loss is demonstrated. The term elevated intraocular pressure is used when an 
intraocular pressure above a defined normal range or an increase from baseline (in 
longitudinal data) is observed. Clinical treatment studies may evaluate either the response 
of active uveitis to a drug or the ability of a drug to maintain inactive disease while other 
drugs are tapered. Other outcome measures (e.g. discontinuation of prednisolone) can also 
be reported. In studies of adult patients, reduction of daily prednisolone to ? 10 mg while 
maintaining inactive uveitis can be considered as the primary outcome for successful 
corticosteroid sparing.107 In children, however, no consensus on such prednisolone doses 
exists. 
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2.3 Conventional treatment in JIA and associated uveitis 
The aim in the treatment of JIA and associated uveitis is prevention of damage to joints 
and eyes, promotion of normal growth and development, resolution of synovitis and 
uveitis, and increasingly, disease remission rather than improvement. Outcome studies 
demonstrate that our treatments in the past have not been as effective as we would have 
liked. Pharmacological therapy of JIA should consider both arthritis and uveitis, as they 
often run independent courses. In an ideal model of treatment, patients are followed by 
both a pediatric rheumatologist and an ophthalmologist. A treatment program should be 
family-centered, and the multidisciplinary team should also include a physical and 
occupational therapist, a social worker, a psychiatrist, and a dentist. 
The current approach to pharmacological treatment of JIA is an initial evaluation of 
severity of disease, followed by early treatment and close monitoring of treatment effect 
during the disease course. The treatment plan needs to be individualized based on JIA 
subtype. For patients with mild disease, such as oligoarthritis without uveitis, there is a 
choice of using intra-articular steroids or nonsteroidal anti-inflammatory drugs (NSAIDs), 
or both. If functional limitations occur, symptoms persist or worsen, or at initial visit the 
patient has already a polyarticular disease, more aggressive therapy should be initiated. 
DMARDs are most often started with MTX monotherapy. In systemic onset JIA, the initial 
therapy is corticosteroids. MTX may work in sJIA-related arthritis, but is usually not 
helpful with systemic features.18, 47
2.3.1 NSAIDs and corticosteroids 
The initial symptomatic first-line therapies in JIA are NSAIDs and intra-articular steroids. 
NSAIDs are used in appropriate daily dose, most commonly naxopren 10-20 mg/kg, 
ibuprofen 20-40 mg/kg, or diclofenac 3-5 mg/kg,128, 129 and are combined frequently with 
DMARDs and/or glucocorticoids. NSAIDs provide analgesic and mild anti-inflammatory 
benefits by inhibiting the cyclooxygenase-2 isoenzyme in the prostaglandin biosynthetic 
pathway. Traditional NSAIDs concomitantly inhibit the cyclooxygenase-1 isoenzyme, but 
are associated with gastrointestinal toxicity. Cyclooxygenase-2 selective inhibitors have 
been associated with less gastrointestinal symptoms and have become a treatment option in 
RA. In a double-blind RCT, the efficacy of meloxicam, which is semi-selective, and 
rofecoxib in JIA was comparable with that of naproxen.130, 131 Due to emerging toxicity, 
such as adverse cardiovascular events in adults, rofecoxib was later withdrawn from the 
market worldwide, as were some other cyclooxygenase-2 inhibitors. 
Intra-articular steroids are an established treatment for arthritis,132, 133 especially for the 
oligoarticular subtype. The long-term efficacy of triamcinolone hexacetonide over 
methylprednisolone has been proven, particularly in knee arthritis.134 Intra-articular therapy 
is complemented with DMARDs and oral/iv corticosteroids when articular or systemic 
symptoms are uncontrolled, persistent, or life-threatening. Due to side-effects, especially 
those affecting bone and growth, the long-term systemic use of steroids is avoided in 
children. Oral glucocorticoids are usually given as low-dose and alternate-day prednisolone 
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(0.1-0.2 mg/kg), the initial dose with severe systemic symptoms being higher (up to 1-2 
mg/kg daily). In severe disease, corticosteroids can also be given as pulse therapy (iv 
methylprednisolone). There is no evidence that systemic glucocorticoids are disease-
modifying. Steroids have both anti-inflammatory and immunosuppressive effects, which 
are mediated by the inhibition of specific functions of leukocytes, such as the action of 
various lymphokines.46
Prolonged intake of steroids may be associated with iatrogenic Cushing’s syndrome, 
fractures, osteoporosis, cataract, immunosuppression, and growth retardation,6, 7, 46
especially during long-term treatment.135, 136 Glucocorticoids disturb longitudinal growth, 
possibly by a direct effect on the receptors of the growth plate137 and/or by interfering with 
other growth-modulating pathways such as the IGF-1 axis.138 In addition, a transient 
suppression of the pituitary-adrenal axis after intra-articular steroid injections has been 
described139 and is suggested to be dose-dependent.140
2.3.2 DMARDs and other disease-modifying drugs 
The increased and earlier use of immunosuppressive drugs has improved the prognosis of 
JIA.5 Apart from single-center and national multicenter trials, during the last decade also 
international complementary networks, such as the Pediatric Rheumatology International 
Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group 
(PRCSG), have facilitated and conducted large multinational drug trials, and provided 
valuable information on disease management. Unsolved issues concerning treatment of JIA 
still exist. For example, we do not yet know whether treatment should be initiated with 
single or combination DMARDs. Patients and their families may adhere better to for a 
monotherapy. However, with a combination the efficacy may be maintained better due to 
synergy. The superior efficacy of combination DMARDs over monotherapy has been 
demonstrated in RA,141 but no comparable studies in JIA have yet been published. Exact 
molecular mechanism of action of most DMARDs in rheumatic diseases is not known.  
Methotrexate (MTX) is the initial second-line agent due to its efficacy and acceptable 
toxicity. After a few noncontrolled studies (Table 4),142-146 a USA/USSR collaborative 
placebo-controlled blinded RCT proved the efficacy of MTX in JIA.147 Another gigantic 
multicenter RCT, including 20 countries, was published recently. Low, intermediate, and 
high doses of MTX were evaluated in 595 JIA patients. Results suggest that MTX should 
be started with a weekly dose of 15 mg/m2, and continued for at least 9-12 months before 
declaring a treatment failure. Initial parenteral dosing has been recommended due to 
variations in the absorption of higher oral doses.20 Other publications on MTX have been 
mostly open-label studies of short-148-151 or long-term efficacy,152 or route of 
administration.19, 153 
Although MTX monotherapy seems to be clinically effective in approximately two-
thirds of patients, radiologic progression of rheumatic disease has been reported in 67-74% 
of patients regardless of clinical outcome and in 80-100% of nonresponders.149, 154 Ravelli 
et al.151 found that patients with extended oligoarthritis responded more often to MTX than 
sJIA or polyarthritis patients. The superior response of extended oligoarthritis compared 
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with sJIA was confirmed by Woo et al.155 in a placebo-controlled blinded RCT. Based on 
modified ACR Pedi30, this trial failed to demonstrate significant improvement in 44 sJIA 
patients, even though certain outcome measures were improved.155 Based on these two 
well-conducted studies, MTX does not seem to be effective in sJIA.151, 155 
MTX induced no serious AEs in any of the studies reviewed in Table 4. The most 
common AEs are nausea, vomiting, mouth sores, loss of appetite, hair loss and malaise.20
One concern with MTX has been potential hepatotoxicity. In all patients receiving MTX, 
regular liver enzyme screening is recommended. Even in patients receiving high-dose 
MTX and multiple DMARDs, the minor abnormalities observed in liver biopsies have 
been reversible, and no signs of fibrosis or cirrhosis have been found.156 In a noncontrolled 
study, folinic acid supplementation concomitantly with MTX reduced episodes of liver 
transaminase elevation and gastrointestinal toxicity,157 and is thus recommended.
Table 4 Efficacy of methotrexate in juvenile idiopathic arthritis. 
Author (year)          n FU  Method Responder rate / Improvement 
Truckenbrodt (1986)19 11 mo retrospective 63% (mostly sJIA), steroid-sparing effect in 53% 
Speckmeier (1989)   12 6 mo open label 33% (sJIA), on 9 mg/m2
Wallace (1989)         23 1.6 y open label 91%, improvement associated with dose ? 0.3 mg/kg  
Rose (1990)              29 1.5 y open label 83% systemic, 48/46% joints w limited motion/swelling  
Halle (1991)             30 1.5 y open label 46% (all responders ANA+) in active joints 
Giannini (1992)       127 6 mo PC DB RCT 65% on 10 mg/m2
Ravelli (1995)          29 6 mo open label 52% reduction of active joints  
Reiff (1995)             21 15 mo open label 33% on mean 27 mg (25 mg/m2) po/ im 
Huang (1996)           26 3 y retrospective 73% (CR or 25% reduction of active joints) 
Ruperto (1998)        111 6 mo open label 66% (preliminary ACR Ped30) 
Ravelli (1998)         257 6 mo open label 58% vs. 61%, po vs. sc  10 mg/m2
Ravelli (1999)         80 6 mo open label 65%, CR in 36% at median of 11 mo  
Woo (2000)             88 4+4mo PC DB RCT 48% in Eo, 25% sJIA (modified ACR Ped30) 
Alsufyani (2004)     61 >3 mo retrospective 66%. Nonresponders to sc-injections, and 76% improved 
Ruperto (2004)        595 6 mo RCT 72% ACR Ped30, 61% Ped50, 38% Ped70, CR 12%  
(No PsA, ERA) 10 mg/m2 po/sc 
Ruperto (2004)        80 
(non-responders)  
12 mo RCT  
(Phase II) 
15 mg/m2: ACR 30-50-70-CR > 63-58-45-13%  
30 mg/m2 : >58-55-48-10% (difference p=ns) 
See “Abbreviations” for further definitions. CR clinical remission, DB double-blind, Eo extended 
oligoarthritis, FU follow-up (mean/median), mo months, PC placebo-controlled, y years   
Several DMARDs have been used or are still in use for JIA patients. The efficacy of 
hydroxychloroquine or aurothiomalate (gold sodium thiomalate) has not been proven in 
children. In a RCT on 72 JRA patients, comparable improvement was observed in those 
receiving hydroxychloroquine, aurothiomalate, and D-penicillamine. Hydroxychloroquine 
was better tolerated than the other drugs. However, in a USA/USSR collaborative trial, 162 
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JRA patients were randomized in a blinded fashion to receive hydroxychloroquine 6 mg/kg 
daily, D-penicillamine, or placebo. At the end of the trial, no differences were found 
between either hydroxychloroquine, penicillamine, or placebo.158 Another blinded placebo-
controlled USA/USSR collaborative RCT, conducted in 231 children, showed no 
significant clinical efficacy with auranofin (oral gold compound) compared with placebo, 
even though auranofin was well-tolerated.159 A 5-year open-label extension trial on 
auranofin also revealed no sufficient therapeutic effect.160 No placebo-controlled studies 
exist on the parenteral gold compound aurothiomalate in children. 
The efficacy of sulfasalazine over placebo in juvenile polyarthritis and oligoarthritis 
has been demonstrated in a 24-week blinded placebo-controlled RCT. Of 69 patients, 75% 
completed the trial. One-third withdrew from the sulfasalazine group mainly due to AEs. 
The most common AEs were gastrointestinal symptoms, which occurred more often in the 
sulfasalazine than in the placebo group, and were in one patient defined as severe.161 Long-
term efficacy of early active sulfasalazine treatment has been evaluated in an extension 
study, where the original cohort was followed for a median of 9 years. At follow-up, 15% 
were in clinical remission off medication, 11% were in clinical remission on medication, 
and 74% had active disease. Those in the initial sulfasalazine group more frequently had 
quiescent disease and were more often ACR Pedi30 responders at follow-up. The authors 
suggested that suppression of active disease by effective early treatment with sulfasalazine 
resulted in beneficial long-term outcome.162 In patients with JSPA, however, no difference 
was found between those receiving sulfasalazine or placebo in a blinded 26-week RCT.163
The efficacy of leflunomide has been evaluated in a blinded RCT including 94 patients, 
where MTX was considered more effective than leflunomide. At 16 weeks, ACR Pedi30 
was reached in 89% of those taking MTX vs. 68% taking leflunomide (p=0.02), ACR 
Pedi50 in 77% vs. 60%, and ACR Pedi70 in 60% vs. 43%, respectively. In an extension 
phase of 48 weeks, favorable responses were maintained, thus reflecting a sustained effect 
of both drugs. Improvement rates in both treatment groups were unexpectedly high, which 
was suggested to be associated with an early stage of disease (median disease duration 4 
months). The safety profile of MTX was better during the initial 16 weeks, although liver 
function abnormalities were less frequent in those on leflunomide.164 A noncontrolled 
open-label study was performed on 27 JIA patients with a history of MTX failure. Of the 
63% of patients completing the study at 26 weeks, 52% were ACR Ped30, 44% ACR 
Pedi50, and 19% ACR Pedi70 responders. In an extension phase (9 completing), ACR 
Pedi30 response was observed in 56% at both 1- and 2-year follow-ups. Reversible 
elevation of liver function tests was noted in 11%.165
No controlled studies on cyclosporine A (CSA) have been published. Ostensen et al.166 
noted that with CSA treatment, disease activity remained virtually unchanged, and 78% of 
14 patients discontinued CSA due to inefficacy or AEs. A few  studies have suggested a 
beneficial effect of CSA, mainly in combination with MTX.167, 168 Ravelli et al.169 reported 
ACR Pedi30 improvement with a combination of MTX and CSA in 47% of 17 MTX-
failures. In an open-label trial, in which 83% of 41 patients had sJIA, one-third 
discontinued CSA due to inefficacy or AEs, and one-fourth due to remission. Side-effects 
were common (hypertrichosis, increased serum creatinine, hypertension, gastrointestinal 
symptoms, gingival hyperplasia), but usually reversible. CSA reduced systemic symptoms 
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and spared glucocorticoids, but had no measurable efficacy on arthritis or uveitis.170 A 
retrospective review included 329 patients (half with sJIA) receiving CSA, given in 
combination with MTX in 61% of patients and in conjunction with systemic prednisolone 
in 65%. At the last follow-up visit, 9% of patients were in remission and 61% had 
moderate or severe disease activity. The reasons for discontinuing CSA were inefficacy in 
61% of patients, side-effects in 22%, noncompliance in 9%, and inactive disease in 10%. 
The overall efficacy profile of CSA was less than satisfactory as a monotherapy and as a 
combination therapy, at least compared with MTX monotherapy.21
A controlled 16-week blinded study of azathioprine in 32 JIA patients did not find a 
significantly greater effect than placebo.171 By contrast, in an uncontrolled trial, Savolainen 
et al.172 suggested that azathioprine did have a beneficial effect in 129 patients, of whom 
38% completed a 2-year follow-up with significant improvement in disease activity, and 
29% achieved remission at least temporarily. In a retrospective review of 24 children, 63% 
showed some clinical improvement and 38% achieved clinical remission during a mean 
treatment time of 13 months.173 Apart from reversible leucopenia leading to treatment 
termination, also more serious AEs have been observed.171-173
In small patient series in refractory sJIA, beneficial effect of thalidomide as single 
therapy174, 175 and cyclophosphamide as single drug176 or in combination with MTX177 was 
reported. In refractory JIA, chlorambucil was suggested to be effective,178, 179 but a high 
mortality rate (6%) and a risk for leukemia180-182 has prevented its further use. In the most 
severe and life-threatening cases of progressive polyarticular and systemic JIA, autologous 
stem cell transplantation has been considered effective,183 but associated with fatal 
complications.184
2.3.3 First-line and second-line therapy in uveitis 
First-line standard therapy for anterior uveitis is topical steroids (prednisolone acetate or 
dexamethasone) and mydriatics, although this recommendation is based on neither 
randomized trials nor controlled studies. The value of prolonged corticosteroids in treating 
uveitis has not been thoroughly explored.185 Of all patients with JIA-associated uveitis, 34-
41% do not respond to intensive topical treatment.126, 186 Early second-line 
immunomodulatory therapy is recommended when quiescence of inflammation is not 
achieved with low-dose topical steroids, or if already at the initial presentation risk factors 
for vision loss are found.14, 185 Recent studies have suggested efficacy of second-line agents 
such as DMARDs. Evidence for the beneficial effect of immunosuppressive treatments in 
chronic uveitis is based on observational studies.  
Efficacy of MTX in treating childhood uveitis has been evaluated in several studies. In 
a noncontrolled study, 6 of 7 patients starting MTX had reduced inflammatory activity of 
uveitis, and glucocorticoid sparing was also noted.187 A retrospective study reviewed 
patients with chronic anterior or intermediate uveitis (none with JIA). During MTX 
therapy, in 9 of 10 children, the AC inflammation was diminished and/or the need for 
topical steroids decreased.188 Authors of another retrospective analysis suggested that 
initiating MTX treatment led to a remission of JIA-associated uveitis in 88% of 25 patients, 
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although some patients flared after discontinuing MTX.186 Heiligenhaus et al.22 observed
quiescent uveitis in 71% of patients taking MTX either with (n=21) or without (n=4) 
topical steroids, but 20% required additional immunosuppressive medication. 
CSA has been used to treat uveitis either as a monotherapy or in combination with 
other DMARDs. Kilmartin et al.189 retrospectively reviewed the charts of 14 patients with 
noninfectious childhood uveitis, 3 of whom had JCA. The report did not specify which 
patients received CSA as a monotherapy or in combination, but nevertheless suggested 
CSA to be effective and well-tolerated.189 A prospective open-label study of JIA patients 
included 7 patients with uveitis. The AC inflammation decreased in 4 (57%) of them, but 
CSA had to be discontinued in 3 patients due to inefficacy.170
 Reports on the efficacy of chlorambucil in refractory uveitis have been 
controversial.190, 191 One report evaluated the impact of mycophenolate mofetil, initiated in 
25 JIA patients, and described the ocular inflammation to be controlled in 36%.192
2.4 Biologic agents in JIA and associated uveitis 
2.4.1 Early effective treatment? 
Approximately 30-40% of JIA patients do not achieve a response of ACR Ped30 on 
DMARDs,19-21, 150 although in some reports the responder rates to early DMARD therapy 
are somewhat higher.164 Moreover, in roughly 20% of those with JIA-associated uveitis, 
ocular inflammation is not controlled by conventional therapy. 22 No improvement criteria 
for uveitis is included in the ACR or ACR Pedi criteria. Measures to evaluate the activity 
of uveitis have been recently standardized but are not universally followed. Refractory 
patients with constantly active disease have the highest risk for developing irreversible 
joint damage, permanent disability, and ophthalmic complications.12, 61, 76 Several 
therapeutic approaches have been proposed for these patients, including parenteral 
administration of higher doses of MTX,20 switching to other second-line agents (alone or in 
combination),21, 165, 172, 174 or administration of third-line therapy; biologic agents.  
Whether the ACR Ped30 improvement is clinically sufficient in JIA is questionable. 
During the 21st century, the goal of treatment has shifted from ‘satisfactory improvement’ 
to complete disease control.18, 47 The reported rate of JIA patients achieving clinical 
remission on and/or off medication in arthritis varies from 11% to 26% with DMARD 
therapy,20, 21, 162, 170, 172 depending on drug and the follow-up period. There is some 
evidence in RA suggesting that an initial therapy with anti-TNF agents, compared with 
DMARDs, results not only in more rapid disease control, but also more often in clinical 
remission later in the course of the disease.193 In JIA, no such evidence is yet available.  
Based on investigations demonstrating superior outcomes in RA in those receiving 
early treatment, many rheumatologists believe that a therapeutic ‘window of opportunity’ 
exists early in the disease when therapies are more effective than later on, yielding better 
outcomes such as clinical remission on/off medication or halting of disease progression.18, 
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162, 193, 194
 A number of studies in RA and some in JIA have demonstrated an alteration of 
disease course with a higher responder rate, less joint damage, or improved outcome in 
patients starting early treatment.162, 164, 195, 196 To establish the concept “the earlier, the 
better”, specific trials showing time-dependent optimal response are still needed. In JIA, no 
published studies on early aggressive combination therapy or early biologic therapy exist.  
2.4.2 Cytokine network in rheumatic inflammation and uveitis 
Overexpression of various cytokines has an important role in joint inflammation and in 
damage to articular tissue. Inflammatory synovitis in JIA is similar to that seen in RA,46
showing angiogenesis, cellular hyperplasia, inflammatory leukocytes, and changes in the 
expression of cell-surface adhesion molecules, proteinases, proteinase inhibitors, and many 
cytokines.197 Various mononuclear cells in subsynovial tissues include T cells, B cells, 
macrophages, dendritic cells, and plasma cells. T cell infiltrates are composed 
predominantly of Th1 type, CD4+ cells, which are important activators of macrophages.46
The prolonged inflammatory process in the synovium leads to a formation of pannus, 
which is a tissue predominated by mononuclear cells and aggressive fibroblast-like (type 
B) synoviocytes. Pannus cells migrate over the underlying cartilage and into the 
subchondral bone, which causes erosions of these tissues.197, 198 In response to pro-
inflammatory cytokines, such as interleukin-1 (IL-1) and TNF?, activated pannus 
macrophages and fibroblast-like synoviocytes produce degradative enzymes, matrix 
metalloproteinases (Figure 2).199 Another important group of extracellular matrix- 
degrading enzymes are cathepsins B, K, and L, which are thought to contribute 
significantly to the joint damage in rheumatic inflammation.200, 201 Bone destruction is 
mainly caused by osteoclasts. In RA, the synovial fluid consists of large amounts of 
receptor activator of nuclear factor kappaB ligand (RANKL). Activated synovial 
fibroblasts secrete RANKL at the site of invasion.202 
Figure 2 Simplified representation of interaction between cells of the immune system and 
synovial fibroblasts mediating joint destruction. IL = interleukin, TNF = tumor 
necrosis factor, CXCL12 = stromal cell derived factor 1?. Modified and reprinted 
with kind permission of Immunology Letters (Karouzakis et al. 2006;106:8-13). 
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Quantitative analysis suggests that there are few T cell derived cytokines (such as IL-2, IL-
17, and interferon-?) in inflamed synovial tissue, but large quantities of  TNF? and IL-1 in 
both synovial tissue and synovial fluid.197, 198 Already in 1991, evidence existed that in RA 
TNF? was locally produced in the lining and deeper layers of the synovium by cells of 
monocyte/macrophage lineage, and that affected chondrocyte metabolism led to cartilage 
degradation.203 Today, TNF? and IL-1 are known to be powerful in vitro stimulators of 
synovial tissue effector functions, including proliferation, metalloproteinase and adhesion 
molecule expression, secretion of other cytokines, and prostaglandin production.197 IL-6 is 
markedly increased in synovial tissue and fluid, and induces bone destruction through 
regulating T lymphocyte production of key osteoclastogenic cytokines and inflammation-
induced bone marrow osteoclast differentiation.204 Pro-inflammatory cytokines also induce 
chondrocytes to produce several other proinflammatory cytokines, including IL-17, IL-18, 
leukemia inhibitory factor (LIF), and chemokines.205
Several studies have assessed blood and synovial cytokine concentrations in different 
JIA subtypes, but results have been inconsistent. The reported therapeutic effect of agents 
inhibiting TNF supports the important role of this specific cytokine in rheumatic diseases 
(Figure 3).
Patients with sJIA seem to have a different inflammatory profile and treatment response 
than other JIA subtypes and even those with adult-onset Still’s disease.31, 206, 207 Those with 
sJIA show no signs of lymphocyte-mediated antigen-specific immune responses, but 
activation of innate immunity appears to be more important. Recent studies have 
documented that IL-1?, IL-6, IL-18, and phagocyte-specific calcium binding proteins 
(calgranulins), known as S100 proteins (S100A8, S100A9, S100A12), correlate with 
disease activity and secondary complications of sJIA.208 The overproduction of IL-6 
correlates with joint involvement and may also explain many extra-articular 
manifestations, including microcytic anemia and growth failure. This has led many 
researchers to suggest that sJIA is an IL-6 mediated disease.47
A controlled study on the cytokine profile in JIA-associated uveitis has been 
performed.209 Compared with controls, those with uveitis had increased levels of, for 
example, IL-2, IL-6, IL-10, IL-13, IL-18, IFN-?, and TNF? in samples of the aqueous 
humor. IL-8 and IL-10 levels were lower in quiescent uveitis and in those taking MTX, 
than in active ophthalmologic inflammation and in those not treated with MTX. No 
significant differences in samples were found in those with or without topical or systemic 
corticosteroids. The authors concluded that in children with uveitis multiple cytokines, 
chemokines, and soluble adhesion molecules were increased in the aqueous humor 
regardless of active or quiescent inflammation.209 In another controlled study, aqueous 
humor and sera of patients with uveitis showed higher levels of TNF? than those of 
controls without uveitis, but TNF? levels were higher in the sera than in the aqueous 
humor. Higher serum TNF? levels were associated with recurrent uveitis. Authors 
suggested that TNF? participates actively in the pathogenesis of clinical uveitis, although it 
seems to have greater systemic than local effects.210
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Figure 3 Cytokine network in rheumatic inflammation. Black arrows represent upregulatory 
effects and red arrows downregulatory effects. Red crosses represent pathways 
blocked by anti-TNF agents. Modified and reprinted with kind permission of Lancet 
(Lee and Weinblatt 2001;358:906). 
In animal models, experimental autoimmune uveoretinitis was shown to be a CD4+ Th1 -
mediated disease.211 A chronically activated T cell is capable of activating neighboring 
cells to produce not only TNF?, but also IL-1 and IL-6, chemokines such as IL-8 and 
macrophage inhibitory factors, and matrix metalloproteinases. In the model, increased 
tissue concentrations of TNF facilitate T cell effector responses and macrophage 
activation, which are responsible for tissue damage and can be suppressed by anti-TNF 
therapies. The ability to suppress disease experimentally has led the way to clinical studies 
in uveitis.211
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2.4.3 Biologic agents in JIA 
During the last decade, a number of well-characterized monoclonal antibodies  and 
recombinant human molecules (e.g. cytokines, cytokine receptors, cytokine inhibitors) 
directed against defined endogenous target molecules have been available. Besides 
investigating disease mechanisms, simultaneous in vivo studies have facilitated 
development of improved therapies. Specific targets of biologic agents have raised hope 
that AEs would be less problematic than in those receiving conventional treatment, which 
have broader immunomodulatory effects. However, some AEs during biologic therapies 
have not been anticipated. A disaster occurred during a phase 1 trial with an anti-CD28 
monoclonal antibody, necessitating intensive care of several subjects due to multi-organ 
failure induced by cytokine release syndrome.212 Thus, especially in children, new 
treatments must be used with caution, and pediatric studies should be initiated only after 
broad toxicity and safety analyses in vivo. In children’s short- and long-term studies, 
effects on growth, maturation, reproduction, cognitive functions, and emotional and 
psychological aspects should be evaluated. Moreover, pharmacokinetics need to be 
assessed separately in children due to potentially marked differences compared to adults.  
Anti-TNF agents etanercept, infliximab, and adalimumab 
TNF is a pivotal cytokine in the pathogenesis of rheumatic inflammation. The first reports 
on TNF? were published in the mid-1980s, and already in 1989 anti-TNF? agents were 
suggested as potential treatment options for RA.213 It was not until 1993 that a therapeutic 
trial by Elliot et al.214 demonstrated that TNF-inhibiting with anti-TNF had a dramatic and 
rapid beneficial effect on patients with RA. This trial was followed by multiple other 
placebo-controlled RCTs in RA patients, in which anti-TNF agents combined with MTX 
demonstrated an ACR20 response in 56%-72% of patients, ACR50 response in 39%-55%, 
and ACR70 response in 19%-27%.215-217 During the recent years, consensus statements on 
the use of biologic agents in rheumatic diseases have been regularly updated.218
Only after larger safety and toxicity assessments in adults, were pediatric trials 
initiated. The first case report on a patient with sJIA receiving TNF inhibitor was published 
in 1997,219 but in 2000 the efficacy of a soluble TNF receptor on polyarticular JIA was 
finally demonstrated.220 Since then a few RCTs and some open-label pediatric trials have 
been reported.  
Anti-TNF agents in children seem to be well-tolerated, but pooled long-term safety 
analyses are not yet available. Clinical experience in adults has provided data that can be 
adapted to children with long-term biologic therapies.221 Some cases of reactivated 
tuberculosis, opportunistic infections, demyelinating diseases, macrophage activation 
syndromes and lupus-like reactions have occurred in children receiving anti-TNF therapies. 
Neither in these conditions nor in the frequency of severe infections and malignancies has 
a markedly increased risk been observed during anti-TNF therapies compared with 
conventional treatments.47, 222, 223 Currently, until more safety data have been published, 
biologic agents are reserved for children with refractory JIA. Nevertheless, patients most 
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likely to respond and less likely to experience serious complications should be identified 
using registry-based data. Moreover, cost-efficacy analyses are few and have provided 
somewhat conflicting results. Although direct costs of biologic treatment are much higher 
than those of conventional therapies, the overall costs may be reasonable in the light of 
improved outcome and reduced indirect costs.224 Anti-TNF agents bind to TNF?,
decreasing its bioavailability. Today, three anti-TNF agents are available for clinical use.  
Etanercept is a recombinant form of the p75 TNF receptor coupled to the Fc fragment 
of human IgG1. Etanercept neutralizes TNF by binding to TNF? and may exert its effect 
by binding other cytokines, including IL-1? and TNF?. It is administered twice weekly, 
one dose being 0.4 mg/kg (max 25 mg) sc. Lovell et al.220 conducted the first placebo-
controlled RCT in 69 refractory JIA patients, 74% of whom achieved ACR Pedi30 at 3 
months. At the end of the 2-year extension phase, 43 patients (74% from the original 
group) were still enrolled, and ACR Pedi30, 50, and 70 were achieved by 81%, 79%, and 
67%, respectively, showing sustained efficacy.225 In a 4-year follow-up, the efficacy was 
higher; 94% of the 32 patients improved up to ACR Pedi30, and 78% up to ACR Ped70.226
In the 8-year open-label trial, ACR Pedi70 response or higher was recently reported in all 
26 patients.227 Currently the only registry-based publication of anti-TNF agents in children 
is from a German etanercept registry, in which ACR Pedi30 was achieved at 6 months by 
83% of the 322 JIA patients, and at 30 months by more than 50% of non-systemic 
patients.228 Two noncontrolled studies have evaluated the efficacy of etanercept in ERA 
and JSPA, and the response has been promising.229, 230 Etanercept seems, however, to be 
less effective in sJIA than in other JIA subtypes.206, 220, 228
Infliximab is a chimeric, partly humanized monoclonal TNF? antibody, which binds 
both soluble and cell-bound TNF?, and may enhance its effect by deleting TNF?-
producing T cells through apoptosis. Infliximab is administered as iv infusions of 3-6 
mg/kg at 6- to 8-week intervals after loading doses at baseline and at 2 weeks. The efficacy 
of infliximab in JIA or JSPA has been documented in small open-label studies,230-232 and 
finally in 2007 in a RCT.223 Although a nonsignificant between-group difference was 
observed during the placebo-controlled phase, results were consistent with a favorable 
risk/benefit profile in adults. In one year, 73% of 122 JIA patients achieved ACR Pedi30, 
70% ACR Pedi50, and 52% ACR Pedi70. AEs occurred less often in those receiving a 
dose of 6 mg/kg compared with 3 mg/kg, although in the efficacy no significant difference 
between the doses was demonstrated.223 Preliminary data of a blinded RCT in JSPA during 
a 3-month trial suggest that in 12 patients receiving infliximab compared with 14 patients 
receiving placebo, inflammatory signs and symptoms decreased significantly (p=0.007). 
AEs were comparable in both treatment groups.233 Of JIA patients receiving infliximab, 
approximately 20% had infusion-related reactions, leading to treatment discontinuation.223, 
231, 232
 Adverse drug reactions and loss of efficacy with infliximab treatment may be 
associated at least partly with the development of anti-chimeric antibodies.223 Thus, no data 
are available on the long-term efficacy of infliximab, on long-term comparisons between 
etanercept and infliximab therapies, or on switching between these agents.  
Adalimumab is a humanized IgG1 anti-TNF? monoclonal antibody that blocks 
interaction with the p55 and p75 cell-surface TNF? receptors. No studies on JIA patients 
have been published. In a long-term study on RA, adalimumab has shown sustained 
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efficacy.234 Highly promising pilot data on a blinded RCT have been reported for 
adalimumab, administered at a dose of 24 mg/m2 (ad 40 mg) every other week.235 At week 
16, 84% of patients achieved ACR Pedi30, 77% ACR Pedi50, 58% ACR Pedi70, and 27% 
ACR Pedi90. During a placebo-controlled phase, significantly more patients in the placebo 
than in the adalimumab group flared. Of 128 patients entering the trial, 75% completed the 
2-year follow-up. Their ACR Pedi30, 50, 70, and 90 responses were sustained up to 2 years 
(94%, 93%, 81%, and 60%, respectively) and were comparable in patients with and 
without MTX.235
Other biologic agents 
When JIA patients do not respond to TNF blockers, other biologic agents may provide 
therapeutic options. Only a few pediatric reports have been published, but several trials are 
ongoing. Encouraging reports on the substantial clinical improvement seen in patients with 
sJIA receiving anti-IL-1 or anti-IL-6 therapies support the hypothesis that the key 
mediators of sJIA are these cytokines instead of TNF?.207, 236, 237 Larger safety analyses on 
pediatric patients are not yet available. Based on adult trials, avoiding the use of anti-TNF 
therapies in combination with other biologic agents is recommended due to the increased 
risk of infections.238 Biological agents are usually combined with MTX to achieve better 
clinical results.218, 238
Anakinra, a recombinant IL-1 receptor antagonist (IL-1RA), is administered as daily sc 
injections of 1-2 mg/kg (ad 100 mg daily). A couple of case series of refractory sJIA 
patients have been published, suggesting favorable responses in 7 of 9 and 6 of 7 
patients.237, 239 However, pilot data on anakinra in juvenile polyarthritis demonstrated no 
efficacy compared with placebo.240 A recent investigation compared patient response to 
anakinra in sJIA and adult-onset Still’s disease. While 73% of 15 adults achieved ACR50 
improvement, only 25% of 20 juveniles showed a comparable improvement.31 Whereas the 
IL-1 blockade has a dramatic and sustained effect in some sJIA patients, many others are 
partial responders or nonresponders, suggesting a different disease pathogenesis that is 
more independent of IL-1 pathway.207
In children with sJIA, blockade of IL-6 signaling has been reported to be more effective 
than treatment with IL-1 blockade.236, 241 Because IL-6 is able to be stimulated by both the 
IL-1 and TNF pathways, it is suggested that IL-6 blockade will take care of processes in 
both pathways.207 Tocilizumab, also called MRA, is a humanized antihuman IL-6 receptor 
antibody of the kappa-IgG1 subclass, designed using genetic engineering technology. 
Tocilizumab recognizes both membrane-bound and soluble forms of human IL-6 receptor, 
thus inhibiting the binding of IL-6 to its receptor and its pro-inflammatory activity.236 It is 
administered as iv infusions, and in a phase III trial the dose was 8 mg/kg every 2 weeks.241
In a phase II trial,  after three infusions 91% of 11 sJIA patients reached ACR Pedi30.236
Thus far published only as an abstract, the subsequent trial with a 6-week open-label phase 
showed ACR Pedi30, 50, and 70 improvement in 91%, 86%, and 68% of 56 sJIA patients. 
Next, 43 patients entered a 12-week double-blind phase, in which tocilizumab proved to be 
more effective than placebo.241 Tocilizumab is not yet in wider use. Its short-term safety 
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reports are promising, and its long-term tolerability is currently being evaluated in an 
extension study. In RA, long-term tolerability and efficacy have been good, but warrant 
further investigations.242
T cell activation requires antigen presentation by antigen-presenting cells (dendritic 
cells, macrophages, or activated B cells) and co-stimulation, such as via CD80 or CD86. 
The two molecules bind to CD28 on T cells, but have higher affinity to cytotoxic T 
lymphocyte antigen 4 (CTLA 4), which is expressed on the T cell after activation and 
mediates T cell downregulation. Abatacept is a recombinant fusion protein, consisting of 
the extracellular domain of human CTLA 4 and part of the Fc domain of human IgG1. This 
CTLA 4 immunoglobulin molecule inhibits T cell activation by binding to CD80 and 
CD86, thereby blocking interaction with CD28.238 During a 4-month open-label phase of 
an ongoing pediatric trial, 65% of 170 JIA patients achieved ACR Pedi30, and abatacept 
was effective in all JIA subtypes: in 68% of seropositive polyarthritis, 64% of seronegative 
polyarthritis, 65% of sJIA, and 59% of extended oligoarthritis. One-third of patients had 
previously experienced failure with anti-TNF agents, and in these patients ACR Pedi30, 
50, and 70 responder rates were 39%, 25%, and 11%, respectively. One patient had 
leukemia, but according to researchers this was unlikely to be related to abatacept. 
Abatacept was well-tolerated in this pilot study.243
Rituximab is a chimeric human/mouse monoclonal antibody directed at the CD20 
antigen expressed on mature B and pre-B cells. It specifically depletes CD20+ B cells via 
several mechanisms and has long been approved for treatment of CD20+ non-Hodgkin’s 
lymphoma.238 Apart from anecdotal reports, no published evidence on the efficacy of 
rituximab in JIA exists. In RA, rituximab is used for anti-TNF failures.244
Various novel targets are currently being investigated, such as IL-15, 17, 18, and 32, 
chemokines or chemokine receptors, Toll-like receptor pathways, and janus-kinase/signal-
transducer and activator of transcription (Jak/STAT) pathways. Several compounds are 
under phase I-III trials in adults; pediatric trials have not yet been conducted. The latest 
TNF inhibitors are certolizumab pegol, a pegylated Fc free anti-TNF agent, and 
golimumab, a human monoclonal TNF? antibody. An older target, IL-1, is still of interest. 
Rilonacept, a long-acting IL-1? inhibitor, and AMG, a human monoclonal antibody to IL-
1R, are being investigated. Denosumab is a humanized IgG monoclonal antibody binding 
to RANKL, which interferes with osteoclast activation. Denosumab has been found to 
inhibit bone erosions without affecting disease activity. Inhibition of cathepsin K may also 
interfere with the erosive process.238
2.4.4 Biologic agents in JIA-associated uveitis 
Anti-TNF treatment has shown promise in the treatment of JIA-associated uveitis, although 
almost all studies concerning children are noncontrolled and patient series are small.  
A meta-analysis of the impact of anti-TNF therapy on anterior uveitis in ankylosing 
spondylitis and data collected from placebo-controlled and open-label studies have recently 
been published.245 The overall exposure to placebo was 71 years in 170 patients and to 
anti-TNF agents 146 years in 297 patients on etanercept and 90 patients on infliximab. The 
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frequency of flares of anterior uveitis during placebo vs. anti-TNF treatment was 15.6 vs. 
6.8 per 100 patient-years (p=0.01). The flares were less frequent during infliximab than 
during etanercept treatment.245 Paradoxically, it has also been suggested that etanercept 
causes uveitis.246 Analysis of US registries revealed that etanercept therapy was associated 
with a significantly greater number of reported uveitis cases than infliximab or 
adalimumab.246 In adults, infliximab has a documented efficacy especially in uveitis related 
to Beçhet’s disease.247
A few studies have evaluated the efficacy of etanercept, a soluble TNF receptor, on 
uveitis in children. A retrospective report of 3 JIA patients,248 a randomized placebo-
controlled trial (n=12),249 and a questionnaire-based survey250 failed to show a treatment 
effect. On the contrary, a mild improvement of ocular inflammation during etanercept 
therapy was found in 60% of 10 children up to 3 months,251 and in 40% up to one year252.
In USA and most of Europe, infliximab, a monoclonal TNF? antibody, is not used off-
label in children, and until recently, publications have been few. In retrospective studies 
with 6 JIA patients in each series, a suppression of ocular inflammation was 
documented.253-255 Kahn et al.256 observed significant improvement in the inflammatory 
activity of chronic uveitis in 100% of 17 children (59% with JIA) during high-dose 
infliximab treatment of 10-20 mg/kg with 1-7 infusions. During a mean follow-up of 14 
months (range 3-34 months) without serious AEs, all reached quiescent uveitis. Topical 
steroids were discontinued in 15 patients (88%). 
Two reports suggest that adalimumab, a humanized monoclonal TNF? antibody, has a 
favorable effect on childhood uveitis. In a retrospective analysis of 18 patients (94% with 
JIA), adalimumab was suggested to control effectively uveitis in 88%.257 Another open-
label study on 14 children, 64% who had JIA-associated uveitis and 36% idiopathic uveitis, 
demonstrated decreased AC cellular flare in 81%, sustained resolution of inflammation in 
65% and worsening in 3% of 26 affected eyes.258
Some studies in children have analyzed larger patient series or compared anti-TNF 
agents. Infliximab in 13 children resulted in better clinical improvement than etanercept in 
11 children, reviewed in a retrospective study with heterogeneous patient sample (57% 
with JIA-associated uveitis).259 Based on retrospective review on 1109 JIA-patients, the 
risk for new-onset uveitis is comparable in patients with or without anti-TNF treatment. 
Although new-onset uveitis occurs more frequently in those receiving etanercept than 
infliximab, this difference has not been shown to be statistically significant.259 In a 
questionnaire-based survey concerning 47 JIA patients with uveitis, good response was 
observed in 47% of 34 patients on etanercept, in 68% of 25 patients on infliximab and in 
100% of 3 patients on adalimumab.260
In adults, dacilizumab, a humanized monoclonal antibody against the IL-2 receptor, 
administered as iv infusions, has shown favorable effects in the treatment of posterior 
uveitis, but a recent small placebo-controlled RCT revealed no benefit.261 The efficacy of 
dacilizumab, anakinra, or rituximab in JIA-associated uveitis remains unclear.  
Although biologic therapies have been proven effective by RCTs in JIA, a similar 
strength of evidence is lacking for uveitis. It is vital that research networks be established 
to facilitate RCTs so that in the future the treatment of JIA-associated uveitis is evidence-
based.
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3  AIMS OF THE STUDY 
The aim of the present investigation of anti-TNF therapies in children with JIA and JIA-
associated uveitis was to evaluate the safety, efficacy, and drug survival with anti-TNF 
therapies etanercept, infliximab, and adalimumab in real-life clinical practice.  
More specifically, the study objectives were as follows:  
1. To evaluate the impact of anti-TNF treatment on growth velocity and bone 
maturation in refractory JIA (I).  
2. To identify the predictors of the change in growth velocity during anti-TNF 
treatment (I). 
3. To assess the impact of first-line biologic therapies etanercept and infliximab on 
JIA-associated uveitis (II).  
4. To evaluate the efficacy of adalimumab, a second-line anti-TNF treatment, in JIA-
associated uveitis, especially in patients refractory to first-line therapy (III). 
5. To evaluate long-term drug survival with anti-TNF agents and predictive factors for 
discontinuation of treatment in patients with JIA and JIA-associated uveitis (IV).  
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4  PATIENTS AND METHODS 
4.1 Subjects (I-IV) 
The study population consisted of JIA patients classified based on revised ILAR criteria27
and JIA patients with chronic anterior uveitis (II, III) defined according to SUN criteria107
(Figure 4, Table 5). The follow-up of patients took place at the Department of Pediatrics 
in three tertiary centers: the Hospital for Children and Adolescents, Helsinki (I-IV); the 
Rheumatism Foundation Hospital, Heinola (I-IV); and the Oulu University Hospital (I, 
IV).  
To evaluate growth during anti-TNF treatment (I), patients aged less than 15 years at 
anti-TNF onset and who had received anti-TNFs for over a year (mean 23.1 months, range 
13-24) were included. Of these patients, 43 were taking etanercept and 28 infliximab. 
Adolescents who had already reached their final height were excluded, as well as were all 
of those who had received GH previously or had ongoing GH treatment. 
Figure 4 Enrollment and follow-up (F/U) of JIA patients in three tertiary centers of pediatric 
rheumatology during 2002-2007 (I-IV).  
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Figure 5 Prevalence and occurrence of uveitis in a cohort of 108 patients with refractory JIA. 
Of 108 patients (II), 95% received anti-TNF therapy since 1999-2001 due to arthritis and 
5% due to refractory uveitis. Two uveitis patients were excluded from the final analyses 
because the onset of uveitis occurred after discontinuation of anti-TNF therapy (Figure 5).
In the study on adalimumab (III), 19 of 20 patients had experienced failure in previous 
biological treatment due to inefficacy (11/11 on etanercept, 13/18 on infliximab) or side-
effects (5/18 on infliximab).  
To evaluate long-term drug treatment survival in the whole cohort (IV), patients aged 
<16 years at first anti-TNF treatment and with at least a one-year follow-up completed by 
the end of year 2005 were included. Mean follow-up with either etanercept (n=105) or 
infliximab (n=104) treatment was 30 months (SD ± 21 months, range 1 to 97). Patients 
who did not fit into any JIA category, or were ? 16 years at anti-TNF onset were excluded.   
4.1.1 Drug therapy 
All patients were unresponsive to previous single or combination DMARDs. The decision 
to start biologic agents was at the discretion of the pediatric rheumatologist in charge. 
Before 2003, the supply of etanercept was limited, and juvenile patients received off-label 
infliximab and later adalimumab. Anti-TNF therapy was initiated on top of concomitant 
DMARDs. During follow-up, DMARDs and oral prednisolone were tapered if neither 
arthritis nor increased ocular inflammation had occurred. Concomitant MTX was given 10-
20 mg/m2 up to 35 mg weekly when no limiting side-effects emerged. Other DMARDs, 
such as sulfasalazine, CSA, azathioprine, or hydroxychloroquine, were chosen instead of 
MTX or in combination with MTX when necessary.  
Local therapy of uveitis included topical corticosteroids and mydriatics, and 
immunosuppressive therapy was most often started with MTX and/or CSA and/or oral 
prednisolone before the initiation of biologic agents (II, III). 
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Table 5 Characteristics of JIA patients concerning drug survival (IV), growth (I), and 
uveitis (II, III) with the biologic agents (BA) of  etanercept (ETA), infliximab (IFX), or adalimumab 




 (I)  ETA / IFX (II) ADA (III) 
Patients (n) 209 71 45 20 
Males 64 (31) 18 (25) 8 (18) 4 (20) 
Type of JIA     
Seronegative polyarthritis 104 (50) 45 (63) 27 (60) 10 (50) 
Seropositive polyarthritis 9 (4) 3 (4) 0 0 
Extended oligoarthritis 42 (20) 19 (27) 14 (31) 7 (35) 
Persistent oligoarthritis 16 (8) 0 3 (7) 1 (5) 
Systemic JIA 13 (6) 2 (3) 1 (2) 1 (5) 
Enthesitis related arthritis 21 (10) 2 (3) 0 1 (5) 
Psoriatic arthritis 4 (2) 0 0 0 
Uveitis 75 (36) 27 (38) 45 (100) 20 (100) 
ANA-positive 88 (42) 31 (44) 29 (64) 15 (75) 
HLA-B27 present 70 (33) 27 (38) 15 (33) 6 (30) 
Age at onset of BA (years) 10.1 ± 3.5 9.6 ± 3.2 10.0 ± 3.1 13.5 ± 3.3 
Duration of JIA (years) 5.8 ± 3.4 5.0 ± 3.6 7.1 ± 3.5 10.1 ± 3.5 
Onset of JIA (years) 5.1 ± 3.5 3.8 ± 2.8 2.9 ± 2.0 3.4 ± 2.1 
No. of DMARDs at baseline 2.1 ± 1.0 2.3 ± 1.0 2.3 ± 1.0 2.3 ± 1.0 
No. of active joints at baseline 8 ± 8 10 ± 9 7 ± 7 10 ± 9 
Prednisolone (mg/kg) at baseline 0.2 ± 0.4 0.2 ± 0.2 0.2 ± 0.2 0.2 ± 0.2 
ESR at baseline (mm/hr) 29 ± 24 32 ± 21 32 ± 23 32 ± 21 
CRP at baseline (mg/l) 23 ± 34 23 ± 25 19 ± 23 23 ± 25 
In the study on growth (II), we assessed total corticosteroid exposure. All doses during the 
four-year follow-up (oral, intra-articular, iv) were summed. Different types of 
corticosteroids were converted into approximate prednisolone equivalents based on their 
glucocorticoid or anti-inflammatory properties, using the following equation: 4 mg 
methylprednisolone = 4 mg triamcinolone = 5 mg prednisolone = 0.75 mg betamethasone 
= 6 mg deflazacort.262
Initial etanercept dose was 0.4 mg/kg twice weekly sc (I, II, IV). Infliximab was given 
80-200 mg (3-6 mg/kg) iv, initially at 2-, 4-, and 6-week intervals and later, based on 
response of arthritis and/or uveitis, every 4-8 weeks or even every 12 weeks (I, II, IV). 
Patients taking adalimumab (III) received a standard dose of 40 mg (0.6-1.5 mg/kg) sc 




All patient charts were reviewed retrospectively (I-IV). Alongside clinical work, part of the 
data were collected prospectively concerning growth velocity and bone age during 2003 
(I), or the efficacy assessment of adalimumab during 2003-2005 (III).   
4.2.1 Assessment of growth and skeletal maturation (I) 
Growth measurements were recorded for four years (two years before and two years from 
the onset of anti-TNF agents). A pediatrician or nurse measured children’s height and 
weight, which were recorded on Finnish growth charts.263, 264 Height standard deviation 
score (HSDS), comparable to height Z-score, was defined as deviation of height, in SD 
units, from mean height for chronologic age and gender.265 Growth velocity was defined as 
a change in HSDS (?HSDS) during the follow-up; positive indicating catch-up growth and 
negative impaired growth. Weights were expressed according to Finnish standards as 
relative weight, i.e. height-adjusted weight, as percentages from the mean ratio in the 
normal population of the same gender and height.265 Body mass index (BMI) was 
calculated as weight (kg) divided by height2 (m2).
An experienced pediatric radiologist determined skeletal maturation using the Greulich-
Pyle method in relation to measurements in Finnish children.266 Normal bone age was 
determined between ± 1 SD based on each patient’s calendar age and gender. Bone age 
was assessed prior to anti-TNF therapy and two years after initiation of therapy.  
For comparative purposes, patients were divided into two categories based on growth 
velocity (?HSDS) for two years before commencement of anti-TNF therapy: those with 
delayed growth (?HSDS < 0) and those with normal or accelerated growth (?HSDS ? 0). 
Parental heights were obtained from patient charts, and midparental target height (V) 
was calculated as follows: 0.0611 x father’s height (cm) + 0.0703 x mother’s height (cm) - 
22.37.267
4.2.2 Criteria for disease activity in JIA (I-IV) 
Inactive disease and clinical remission were defined based on international guidelines.104 A 
pediatric rheumatologist examined the patients every 8-24 weeks (I-IV), depending on the 
activity of the disease. At each visit, the number of active and swollen joints, ESR, CRP, 
and laboratory tests for drug safety were assessed (I-III). Physician’s VAS, 
parents’/patient’s VAS, and CHAQ were evaluated. Improvement of arthritis during 
adalimumab (III) was assessed by ACR Pediatric criteria.100
For comparative purposes (IV), we decided to divide patients into two categories (high 
or moderate) according to baseline disease activity parameters. High activity was defined 
as ? 3 of the following: patients with ? 5 active joints or erosive arthritis, CRP ? 40 mg/l, 
ESR ? 30 mm/hr, number of DMARDs ? 2, prednisolone ? 0.3 mg/kg, sight-threatening 
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uveitis with macular edema, and/or activity of uveitis ? grade 3+.107. Moderate activity was 
defined as patients with increased disease activity, but less than in those with high activity. 
4.2.3 Evaluation of uveitis (II, III) 
Based on current guidelines, an ophthalmologist examined all JIA patients every 3-4 
months (< 7 years of age), yearly (7-12 years), or every 1-2 years (> 12 years). Those with 
uveitis were examined every 2-12 weeks, depending on the activity of uveitis, including 
BCVA (range from 0-1.0), biomicroscopy of the anterior segment of the eye, and 
evaluation of cells and aqueous flare. Posterior parts of the eye were examined by dilated 
indirect ophthalmoscopy or by a Volk 90D lens. Ocular pressure was measured by 
applanation tonometry. Ocular complications (cataract, glaucoma, cystoid macular edema, 
and band keratopathy) were registered. 
A flare in uveitis was defined as an episode with worsening activity in AC 
inflammation during follow-up (II, III). Tapering of topical steroids or concomitant 
immunomodulators had no influence on the evaluation of outcome. The decrease or 
increase in activity of uveitis was based on modified criteria, as in older recommendations 
(II, III)268, 269 or on SUN criteria, as in recent recommendations (III)107 (Table 6). We used 
these two criteria in the studies II-III due to the publication of the SUN guidelines in 
between data collection phases of II and III.  
In the former method, an improvement was defined as a reduction of inflammation by 
at least one grade, and a worsened activity as increased inflammation by at least one grade, 
worsening of visual acuity, development of ocular complications, or a first course of 
uveitis during biologic therapy. If one eye improved, but in the other the activity improved, 
the interpretation was improved activity. 
In the latter method based on SUN criteria,107 improved activity of uveitis was defined 
as either a two-step decrease in the level of inflammation or a decrease to inactive level 
(grade 0), and a worsening of the inflammation as either a two-step increase in the level of 
inflammation or an increase to the maximum grade (4+). If one eye improved, but the other 
eye worsened, the interpretation was improved activity. 
Table 6 Anterior chamber (AC) inflammation in uveitis based on SUN criteria [107] or 
modified criteria [268, 269]. 
SUN criteria Modified criteria 
grade AC cells grade AC cells 
0 < 1 0 < 3 
0.5+ 1-5   
1+ 6-15 1 3-10 
2+ 16-25 2 11-30 
3+ 26-50 3 > 30 
4+ > 50   
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Baseline evaluation of ocular activity was performed when treatment with the anti-TNF 
agent in question commenced (II, III). In the study on etanercept and infliximab (II), the 
endpoint evaluation of ocular activity was performed at 24 months or at the termination of 
the first-line anti-TNF agent. Additionally, the number of all uveitis flares during the 
follow-up was recorded. The mean follow-up was 21 (SD ± 6, range 6-24) months.  
In the study on adalimumab (III) as the first-line (n=1), second-line (n=9), or third-line 
(n=10) anti-TNF agent, the endpoint evaluation was performed either at the end of follow-
up or at the termination of adalimumab. The number of flares was assessed from one year 
before adalimumab to baseline and from baseline to the end of follow-up. The mean 
follow-up was 19 (SD ± 10, range 5-36) months. For comparative purposes, we evaluated 
AC inflammation with both modified and SUN criteria.   
4.3 Statistics (I-IV) 
Results were reported as mean or median with 95% confidence intervals (CI) or 
interquartile range, respectively, and in selected cases with range. The nature and 
distribution of each variable were the basis of choosing an appropriate test for assessing 
statistical differences. Only two-sided tests were used, and the level of significance was 
5%. Differences between categorical variables were tested with Chi-square (χ2) and 
Fisher’s exact tests, or between dichotomous variables in related samples with McNemar’s 
test. In continuous variables, normality was assessed using Kolmogorov-Smirnov’s test 
and equality of variances with Levene’s test. In small samples (n < 30) and in those with 
nonnormal distribution or nonequal variances, differences between groups were compared 
with nonparametric tests; between two independent samples by Mann-Whitney’s U-test, 
between >2 samples by Kruskall-Wallis test, and between two related samples by 
Wilcoxon’s Signed-Rank test. Otherwise independent-samples T-test or paired-samples T-
test was used for comparison. The association between variables was tested by either 
Pearson’s or by nonparametric Spearman’s correlation test.  
More specifically, in the study on growth (I), Finnish growth charts were used as a 
standard mean.263, 264 The growth velocities in patients with delayed or normal growth were 
compared using paired samples T-test. Correlations between growth velocity and disease-
related variables were assessed with Spearman’s test. The effect of glucocorticoids and 
disease-related variables on growth velocity was calculated by multivariate linear 
regression analysis.  
In the study on uveitis (II), comparison of etanercept and infliximab was performed by 
Fisher’s exact test for the outcome of AC activity and by Mann-Whitney’s U-test for 
difference in the number of flares/year before and during biologic treatment.  
In the study on adalimumab in uveitis (III), differences between the number of 
flares/year and disease activity parameters before and during adalimumab therapy were 
compared using Wilcoxon’s Signed-Rank and McNemar’s tests. Spearman’s correlation 
coefficient (rs) was assessed between favorable response or change in the number of 
flares/year and disease-related parameters. Linear and logistic regression analyses were 
performed to estimate predictors or independent variables correlating with change in 
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number of flares and favorable outcome, respectively. Differences in patient characteristics 
between those with good or poor outcome on adalimumab were compared with Mann-
Whitney U-test or Fisher’s exact test.  
In the study on treatment survival (IV), two separate analyses were performed; the first 
on all patients with their first anti-TNF agent and the second focusing on patients during 
the second anti-TNF agent. Kaplan-Meier analyses illustrated treatment survival; i.e. 
continuation rates (%) while on a drug. Comparison of differences between first-line anti-
TNFs were based on log-rank statistics in nonadjusted, and gender- and disease activity-
adjusted models. Adjusted values were presented because some of the baseline 
characteristics were different between the two treatment groups. The comparison between 
the first and the second courses of treatment was based on McNemar's test. Predictors of 
treatment discontinuation were assessed by proportional hazards model (Cox's regression) 
using hazard ratios (HRs). Factors included in Cox models were baseline anti-TNF agent, 
age, duration of JIA, gender, JIA subtype, RF, ANA, HLAB27, uveitis, CRP and ESR at 
baseline, number of DMARDs, number of active joints, prednisolone/kg at baseline, and in 
analyses of the second anti-TNF, also the first anti-TNF agent and the reason for its 
discontinuation.
Statistical analyses were performed with SPSS 12.0 (I, II) or 14.0 (III, IV) for 
Windows. 
4.4 Ethical considerations and registry aspects 
Approval to keep a temporary register of JIA patients on biologic agents, including data 
from three tertiary centers in Finland, was granted by the Finnish Ministry of Social Affairs 
and Health (I-IV). Some data on drug efficacy (III) was obtained from ROB-FIN, which 
has been authorized by the Ethical Committee of the Helsinki University Central Hospital. 
To join this national registry, each patient’s parents or legal guardian and patient 
him/herself (if aged more than seven years and able to write) gave written informed 
consent.
In the beginning of data collection phase, no registry-based data on anti-TNF agents in 
children existed. After founding in 2005 the children’s registry for biological agents as an 
amendment to a formerly founded adults’ registry for biological agents (ROB-FIN), all the 
previously collected data appropriate to this national registry were transferred to ROB-FIN 
after obtaining informed consent. Long-term registries are needed to monitor the toxicity 
and long-term effects of biologic agents. In international consensus guidelines, national 
registries for biologic agents are strongly recommended.218
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5  RESULTS 
5.1 Growth during anti-TNF treatment (I) 
At initiation of anti-TNF treatment, of 71 patients 53 had delayed growth velocity and 18 
normal or accelerated growth velocity. No significant differences existed between these 
two groups in baseline characteristics. At the end of follow-up, 52% of all patients had 
inactive disease, and in addition, in 24% of patients the number of active joints and ESR 
and CRP had decreased by at least 70%, in 17% by 30-69%, and only in 7% by less than 
30%. In the whole group, mean ESR had decreased from 32 to 14 mm/h (p<0.001), mean 
CRP from 23 to 8 mg/l (p<0.001), and mean number of active joints from 10 to 2 
(p<0.001). No serious AEs or side-effects were recorded. 
5.1.1 Change in growth velocity (I) 
For the whole group of 71 patients, a significant increase in the change in growth velocity 
(?HSDS) was observed. This change was due to the increase in ?HSDS in the 53 patients 
with previously delayed growth, whose annual mean ?HSDS increased by +0.45 (95% CI 
0.33 to 0.56, p<0.001) between two years before and two years after the commencement of 
anti-TNF therapy. In the 18 patients with previously normal growth, mean ?HSDS was 
+0.05 (95% CI -0.07 to 0.16, p=0.39). At two years of anti-TNF therapy, both HSDS and 
?HSDS (Figure 6) were comparable between these patient groups. If calculations were 
performed as cm/year, the increase in growth was +1.8 cm/year (95% CI 1.2 to 2.3, 
p>0.001) in patients with previously delayed growth.   
Figure 6 Mean (95% CI) change in growth velocity (?HSDS) 2 years before (-2 to 0) to 2 years 
(0 to 2) after commencement of anti-TNF therapy in JIA patients with previously 
delayed or normal growth. Modified and reprinted with kind permission of Annals of 
Rheumatic Diseases (Tynjälä et al. 2006;65:1044-9). 
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Figure 7 Relationship between annual height velocity two years before and two years after anti-
TNF treatment commenced. The patients in quadrant A previously had delayed 
growth, but experienced catch-up during anti-TNF therapy, and those in quadrant D 
had delayed growth velocity both before and after anti-TNF therapy. Reprinted with 
kind permission of Annals of Rheumatic Diseases (Tynjälä et al. 2006;65:1044-9). 
Of the 71 patients, in 54 (76%) during anti-TNF treatment growth velocity improved. Of 
these 54 patients, 40 had previously had delayed growth, but experienced catch-up after 
anti-TNF treatment commenced (Figure 7, quadrant A). Their ?HSDS was +0.59 
?HSDS/year (95% CI 0.47 to 0.69, p<0.001, range +0.1 to +1.89). Of the remaining 17 
patients, 14 (20%) had normal or accelerated growth velocity throughout follow-up (Figure 
7, quadrant B), 13 (18%) had decelerated growth velocity both before and after anti-TNF 
treatment (Figure 7, quadrant D), and 4 (6%) had normal growth velocity before, but a 
decrease after the initiation of biologic drugs (Figure 7, quadrant C). Higher 
glucocorticoid dose together with older age and poor response to anti-TNF therapy were 
associated with decelerating growth velocity.  
To ensure that increased growth velocity was unrelated to pubertal growth spurt, 
?HSDS was analyzed in girls aged < 7 years and boys aged < 9 years at commencement of 
anti-TNF therapy. Of such patients, ?HSDS increased by +0.85 (95% CI 0.62 to 1.07, 
p<0.001) in 13 with previously delayed growth. Furthermore, 37 patients were prepubertal 
based on the observation that delayed bone age is associated with delayed pubertal 
development.270 Boys with bone age < 13 years and girls with bone age < 11 years were 
included, and in 26 (70%) with previously delayed growth, ?HSDS increased by +0.54 
(95% CI 0.35 to 0.73, p<0.001).  
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Height-adjusted relative weight increased significantly in patients with delayed growth 
from +11.2% to +15.4% (95% CI 0.7 to 7.6, p=0.018), but insignificantly (p=0.467) in 
those with normal growth. BMI increased significantly from 18.3 to 19.7 kg/m2, and 
especially in patients with delayed growth by + 1.5 kg/m2 (95% CI 0.9 to 2.0, p<0.001). 
During anti-TNF treatment, seven patients, six of whom were obese before commencement 
of treatment (BMI > 25 kg/m2 and relative weight > 40%), gained weight excessively. BMI 
increased by +5.3 (range 2.7-8.1) kg/m2 and mean relative weight by +26% (range 12-
39%). Compared with others, these obese patients had earlier onset of JIA (mean 1.7 years) 
and longer disease duration (mean 9.2 years).  
In patients receiving etanercept vs. infliximab, ?HSDS and changes in height-adjusted 
relative weight and BMI were comparable. 
5.1.2 Skeletal maturation (I) and target height (V) 
Bone age was measured at anti-TNF treatment initiation and two years after initiation from 
24 (34%) and 63 patients (89%), respectively. In those with both measures available, the 
stage of skeletal maturation was comparable in 17 (71%), changed from delayed to normal 
in 6 (25%), and from normal to advanced in one (a girl with relatively early puberty). Thus, 
none had any abnormal progression of skeletal age. At two years from anti-TNF initiation, 
bone age was normal in 70% of the 63 patients, delayed in 27%, and advanced in 3%.  
Midparental target height was available for 39 patients (Figure 8). Throughout follow-
up, the difference between actual HSDS and target height persisted; the mean difference 
being greatest at anti-TNF initiation; -1.45 HSDS (95% CI -1.8 to -1.1, p<0.001). Growth 
retardation, i.e. height below -2 HSDS, was observed in 10/71 patients (14%) at 2 years 
before anti-TNF initiation, in 16 (23%) at initiation, and in 16 (23%) at two years after 
initiation. Of these patients, 7, 13, and 14 belonged to the group with delayed growth, 
respectively.  
Figure 8 Median, interquartile range, and range of height SDS (HSDS) at -2, 0, and 2 years in 
relation to anti-TNF onset and midparental target height (Target HSDS) in 29 JIA 
patients with delayed and 10 patients with normal growth velocity. Median, 
interquartile range, and range are depicted as a bar, box, and whiskers, respectively, 
and outliers are shown as circles above or below the range (V). 
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5.1.3 Predictors of change of growth velocity (I) 
Cumulative glucocorticoid exposure (oral, iv, and intra-articular) before and after anti-TNF 
therapy was carefully reviewed. No differences in steroid doses were found between 
patients with delayed growth and those with normal growth. During anti-TNF therapy, 
decrease in glucocorticoid intake was significant in both groups (p<0.001). The 
relationship between ΔHSDS and change in corticosteroid doses in those with delayed 
growth was weak (r = -0.051), and in those with normal growth moderate (r = -0.670). In 
linear regression analyses of all patients, the change in glucocorticoid doses had a weak 
age-adjusted relationship with ΔHSDS (r = -0.27 [95% CI: -0.47 to –0.04]). In those with 
delayed growth, this association was not significant, but in those with normal growth 
strong (r = -0.76 , p<0.001).  
In multivariate linear regression analyses, cumulative four-year oral prednisolone 
(mean 4.9 g, range 0-18.0 g) and four-year intra-articular steroid dose (mean 1.4 g, range 
0.1-3.9 g) were weak predictors for ΔHSDS (r = -0.33 and r = -0.26, respectively). 
However, the most important predictor was growth velocity prior to anti-TNF therapy (r = 
-0.83). Another significant predictor was ESR at two years from anti-TNF initiation, 
reflecting the response to therapy. However, number of active joints or CRP at any 
timepoint during follow-up could not predict ΔHSDS. 
5.2 Anti-TNF agents in JIA-associated uveitis (II, III) 
5.2.1 Occurrence of uveitis in refractory JIA (II) 
The cohort of 108 refractory JIA patients, 60% of them with polyarthritis and 31% with 
extended oligoarthritis, was followed from 1999 to 2005. Uveitis was observed in 47 
patients (44%) (Figure 5 in Methods). Two patients were excluded from final analyses 
because their first uveitis flare occurred after terminating anti-TNF agents. However, a 
comparison of patients with (n=47) and without (n=61) uveitis was performed. At anti-
TNF initiation, baseline demographics were comparable, except for the lower number of 
active joints (7 vs. 11, p=0.003), the higher frequency of ANA positivity (63% vs. 29%, 
p<0.001), the younger age at JIA onset (2.8 vs. 4.8 years, p<0.001), and the longer duration 
of JIA (7.0 vs. 5.5 years, p=0.028) in those with uveitis.  
Five patients had their first course of uveitis during anti-TNF treatment and 
concomitant MTX; 4 on etanercept and 1 on infliximab. At the time of first uveitis flare, 
etanercept doses were consistent with current recommendations, but infliximab dose was 
below the recommended level (2.4 mg/kg). The inflammation resolved in 10 months after 
doubling the infliximab dose. Occurrence of new cases of uveitis per 100 patient-years was 
1.1 (95% CI 0.03 to 5.54) during infliximab therapy and 2.2 (95% CI 0.59 to 6.13) during 
etanercept therapy, this difference being nonsignificant (p=0.600). 
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Table 7 Ophthalmologic characteristics and complications in patients with uveitis 
receiving etanercept or infliximab (II) or adalimumab (III). Data is expressed as number (%) or 
mean (range) at initiation of anti-TNF therapy (baseline) or at the end of follow-up (F/U).  
 etanercept or infliximab adalimumab 
n  45 20 
Bilateral uveitis 34 (76) 20 (100) 
Age at onset of uveitis (years)   6 (1 - 17) 5   (1 - 14) 
Age at anti-TNF onset (years) 10 (3 - 16) 13 (6 - 19) 
Age at onset of first anti-TNF (years) 10 (3 - 16) 11 (3 - 19) 
Duration of uveitis (years) 4 (-4 - 13) 9  (3 - 15) 
Interval: onset of JIA - uveitis (years)  3 (-4 - 15) 1.2   (-4 - 12) 
Uveitis before arthritis 7 (16) 3 (15) 
Baseline End of F/U Baseline End of  F/U 
Visual acuity  0.91 (0.2–1.0) 0.93 (0.1–1.0) 0.96 (0.7–1.0) 0.99 (0.8–1.0) 
Cystoid macular edema  5 (11) 8 (18) 8 (40) 8 (40) 
Cataract  18 (40) 25 (56) 11 (55) 14 (70) 
Glaucoma  6   (13) 13 (29) 10 (50) 11 (55) 
Band keratopathy 5   (11) 7   (16) 8 (40) 8 (40) 
5.2.2 Ophthalmologic characteristics and complications (II, III) 
Between infliximab and etanercept treatment groups, no significant differences in ocular 
complications or visual acuity existed at baseline, despite glaucoma in 6 patients starting 
infliximab vs. in 0 of those starting etanercept (p=0.007). JIA onset occurred earlier in 
those on etanercept (mean 2 years, range 1-6) than in those on infliximab (mean 4 years, 
range 1-9, p=0.016). In baseline characteristics (Table 7), no other differences were 
observed. During two-year anti-TNF therapy, however, the frequency of ocular 
complications increased. One patient taking etanercept had sight-threatening macular 
edema and another had retinal ablation (II). 
At adalimumab initiation 10 patients had complicated uveitis (Table 7). Ten had 
undergone ocular surgery before and three during follow-up, one of whom had an acute 
attack of ocular hypertension, hypopyon, and decrease in BCVA. Other ocular 
complications were also observed: in three eyes cataract and in one eye an increase of 
macular edema with decreasing BCVA (III). 
5.2.3 Etanercept and infliximab in JIA-associated uveitis (II) 
Inflammatory activity of uveitis improved more frequently in those taking infliximab than 
in those taking etanercept (Table 8). The number of AC cells decreased more often in the 
infliximab treatment group (p=0.047), as did also the number of uveitis flares/year 
(p=0.015).
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Table 8 Activity of uveitis during etanercept and infliximab therapy at the end of follow-up 
compared with baseline: the change in number of anterior chamber cells and flares/year, based on 
modified criteria [268, 269]. Modified and reprinted with the kind permission of Annals of 
Rheumatic Diseases (Tynjälä et al. 2007;66:548-50).  
We found no correlation between dose or frequency of infliximab infusions and 
ophthalmologic outcome. Of the 9 well-responding patients, the mean dose was 3.5 (range 
2.8-4.7) mg/kg, and infusion intervals were 4 weeks in 2, 6 weeks in 4, 8 weeks in 2, and 
10 weeks in 1 patient. Of the 4 patients with worsening AC activity, the mean dose was 3.2 
(range 2.4-4.9) mg/kg, and infusion intervals were 4 weeks in 1 and 6 weeks in 3 patients. 
In the 8 patients with no change in AC activity, the mean dose was 3.5 (range 2.9- 4.0) 
mg/kg, and infusion intervals were 6 weeks in 2 and 8 weeks in 6 patients (V). 
Anti-TNF therapy was discontinued due to AEs in 2 patients taking etanercept (rash 
and recurrent skin infections in one and retinal ablation in the other) and in 4 patients 
taking infliximab (infusion reactions in 3 and an increase in DNA-Ab with alopecia in 
one). Discontinuation due to inefficacy occurred in 4 patients on etanercept and in 4 
patients on infliximab, and due to inactive disease (arthritis and uveitis) in 2 patients on 
infliximab. The latter 2 patients remained in clinical remission on DMARDs for 5.2 and 
0.5 years, respectively.  
Severe AEs were observed in 4 patients taking etanercept (pneumonia, unspecified 
abdominal infection requiring hospitalization, sight-threatening macular edema, retinal 
ablation) and in 3 patients taking infliximab (peritonsillar abscess, pansinuitis, and alopecia 
with highly increased DNA-Ab). No life-threatening AEs were observed.  
5.2.4 Adalimumab in JIA-associated uveitis (III) 
Adalimumab was initiated due to uveitis in 5, active uveitis plus arthritis in 11, and arthritis 
in 4 patients. In 19 patients, the first-line biologics had started a mean of 38 months (range 
16-67) earlier, and altogether 18 had taken infliximab prior to adalimumab. Based on SUN 
criteria,101 the activity of uveitis improved in 7 patients. The one whose activity worsened 
had active arthritis throughout the follow-up (Table 9).
Compared with nonresponders, those with improved activity were younger (11.0 vs. 
14.7 years, p=0.046), had shorter duration of JIA (7.4 vs. 11.3 years, p=0.019), and a lower 
active joint count at baseline (1.7 vs. 4.9 joints, p=0.041), but not at the end of follow-up 
(0.7 vs. 2.6 joints, p=0.086). No differences in the use of DMARDs or corticosteroids were 
observed between responders and nonresponders. We found a negative association between 
Activity of uveitis  
Etanercept 
n = 24 
Infliximab 
n = 21 Total 
Worsened activity, n (%) 13  (54) 4   (19) 17  (38) 
No change, n (%) 6    (25) 8   (38) 14  (31) 
Improved activity, n (%) 5    (20) 9   (43) 14  (31) 
Flares/year during therapy, n (range) 1.35 (0-3.2) 0.68 (0-2.0) 1.1 (0-3.2) 
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favorable outcome and duration of JIA (rs = -0.52, p=0.019), active joint count at baseline 
(rs = -0.534, p=0.015), and active joint count at follow-up (rs = -0.47, p=0.036), but not 
with the change in number of active joints. 
Table 9  Activity of uveitis based on either SUN criteria (1) or modified criteria (2) during 
adalimumab therapy in 20 JIA patients with bilateral uveitis. 
The mean number of uveitis flares/year decreased from 1.9 (range 0-12) before 
adalimumab to 1.4 (range 0-11.7) during adalimumab treatment. This decrease was 
insignificant (p=0.186) in all 20 patients, but closer to significance in patients with positive 
ANA (p=0.076) or negative HLA-B27 (p=0.084). The decrease was, however, significant 
in all 20 patients when variables were dichotomized with a cut-off point of one flare/year 
(p=0.039 in McNemar’s test), especially in those with positive ANA (p=0.016), but not in 
those with negative HLA-B27 (p=0.219). We observed neither significant associations nor 
predictors of the decrease in number of uveitis flares/year.  
Altogether 7 of 20 patients discontinued adalimumab during follow-up, 6 because of 
inefficacy (1 flare in uveitis, 1 flare in arthritis, 4 in both) and 1 because of subsiding 
uveitis and arthritis. In this patient, after 4 months arthritis was still in remission, but 
uveitis had relapsed (AC cells 1+/1+). Due to increased inflammatory activity, 4 patients 
were on weekly adalimumab dose of 40 mg without clear improvement in either uveitis or 
arthritis. Of these, 2 discontinued adalimumab due to inefficacy, 1 continued on a weekly 
dose, and 1 switched back to a standard dose because of recurrent respiratory infections. In 
one patient after the start of weekly adalimumab, uveitis became inactive.  
Only 5 patients received oral prednisolone at the end of follow-up. Seven patients were 
able to discontinue prednisolone during adalimumab treatment, and 1 had to increase the 
dose. In all 20 patients, mean daily prednisolone intake decreased from 0.1 mg/kg (range 0-
0.4) to 0.03 (range 0-0.3) mg/kg (p=0.057). Altogether 4 patients were able to switch from 
combination DMARDs to monotherapy, and in 3 of them the activity of uveitis and 
arthritis further decreased.
We observed no serious or life-threatening AEs. The calculated adalimumab exposure 
was 31 patient-years. Thirty infections (0.97 per patient-year) were recorded, most 
commonly upper respiratory infections. Two patients required oral antiretroviral treatment 
(varicella, recurrent herpes zoster), one antrostomy (recurrent sinusitis), and one 
gastroduodenoscopy (gastritis). 
Activity of uveitis on adalimumab SUN criteria (1)  All eyes (1) Modified criteria (2) 
n 20 40 20 
Improved activity, n (%) 7   (35) 8   (20) 11 (55) 
No change, n (%) 12  (60) 32  (77) 3  (15) 
Worsened activity, n (%) 1      (5) 1     (3) 6  (30) 
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5.3 Impact of anti-TNF agents in arthritis (V, III) 
5.3.1 Impact of etanercept and infliximab in arthritis (V) 
Of the original cohort of 108 patients with JIA, altogether 45 had uveitis during etanercept 
and infliximab treatment. Of these 45 patients, at the end of 24-month follow-up or at the 
termination of anti-TNF therapy, 18/45 patients (40%) had inactive arthritis, and only 
10/45 patients (20%) clinical remission including quiescent uveitis (AC cells < 3). In 20/45 
patients (43%) number of active joints, ESR and CRP had decreased by at least 70% but 
less than 100%, in 20 (43%) by at least 30% but less than 70%, and in 13 (29%) by less 
than 30%. Of these 13 patients with poor response to anti-TNF therapy in arthritis, uveitis 
improved in 3 and worsened in 6 patients. At baseline 63 patients without uveitis had more 
active joints compared with those with uveitis (Table 10). Disease activity parameters 
(CRP, ESR, number of active joints) were comparable during etanercept and infliximab 
treatment both at baseline and at the end of follow-up.  
Table 10 Activity of arthritis and inflammation parameters, expressed as mean (range), at 
anti-TNF initiation (baseline) and at the end of follow-up. Cohort consists of 108 JIA patients, of 
whom 45 had also JIA-associated uveitis during anti-TNF treatment (V). 
 Uveitis Without Uveitis p 
 n = 45 n = 63  
CRP at baseline (mg/l) 20  (5-63) 31  (5-159) 0.086 
CRP at 24 months (mg/l) 8    (5-53) 13  (5-142) ns 
ESR at baseline (mm/hr) 32  (2-95) 36  (3-127) ns 
ESR at 24 months (mm/hr) 18  (2-98) 15  (2-99) ns 
Number of active joints at baseline 7    (0-36) 11  (2-47) 0.003 
Number of active joints at 24 months 2    (0-7) 2    (0-21) ns 
Oral prednisolone at baseline (mg daily) 0.2 (0-0.9) 0.2 (0-1.7) ns 
Oral prednisolone at 24 months (mg daily) 0.1 (0-0.2) 0.1 (0-0.5) ns 
5.3.2 Efficacy of adalimumab in arthritis (III) 
At the initiation of adalimumab therapy, 14/20 (70%) patients had active joints. At the end 
of follow-up for adalimumab, 6/14 patients (43%) had inactive arthritis and normal ESR 
and CRP. ACR Pedi30 response was observed in 57% at 6 months, in 60% at 12 months, 
and in 100% at 24 months (Figure 9). During adalimumab therapy, the decrease in number 
of active joints was significant (p=0.002), but not in ESR, CRP, CHAQ, or physician’s and 
parents’/patient’s VAS. Differences in outcome of arthritis were not explained by age, 
duration of JIA, type of JIA, ANA, HLA-B27, gender, number of DMARDs, 
corticosteroids, or onset of JIA. 
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Figure 9 Proportion (%) of ACR pediatric 30, 50, and 70 responses in patients with JIA-
associated uveitis and active arthritis. Number (N) of patients at each time-point is 
depicted at the top of the graph. Reprinted with kind permission of Rheumatology 
(Tynjälä et al. 2008;47:339-44). 
Proportion of patients with clinical remission increased during adalimumab treatment. The 
number of patients with inactive disease increased from one patient at anti-TNF initiation 
to two patients at the end of follow-up if AC grade 0/0 was required for the definition of 
quiescent uveitis and clinical remission. However, the number of patients with clinical 
remission increased from 5 to 11 if that was defined as quiescent arthritis and quiescent 
uveitis with AC grade 0.5+/0.5+.104
5.4 Drug survival with anti-TNF agents (IV) 
Long-term drug treatment survival was evaluated in 209 JIA patients receiving etanercept 
or infliximab as first-line anti-TNF therapy. For statistically meaningful comparisons, 
baseline characteristics of each treatment group were first evaluated. Compared with 105 
patients taking etanercept, the 104 on infliximab had more frequently JIA-associated 
uveitis (29% vs. 43%, p=0.031), persistent oligoarthritis (1% vs. 14%, p=0.001), and ANA 
positivity (35% vs. 51%, p=0.024), less often sJIA (11% vs. 2%, p=0.019) or seronegative 
polyarthritis (p=0.013), and were older at JIA onset (4.5 vs. 5.6 years, p=0.023).  
Baseline differences between genders occurred. Compared to females, males had less 
seronegative polyarthritis (8% vs. 42%, p<0.001), more ERA (10% vs. 0%, p<0.001), and 
fewer were ANA-positive (9% vs. 34%, p=0.022). Moreover, JIA onset in males occurred 
later (6.2 vs. 4.6 years, p=0.018) and its duration was shorter (4.2 vs. 5.4 years, p=0.007).  
At baseline, the proportion of patients with high disease activity receiving etanercept 
and infliximab was 86% and 75%, respectively (p=0.155). The rest of the patients had 
moderate disease activity. Of the 209 patients, 205 (98%) received at least one DMARD; 
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27% were on single and 64% on combination therapy. Of the 205 patients, 166 were on 
MTX, 71 on hydroxychloroquine, 60 on CSA, 51 on sulfasalazine, 30 on azathioprine, and 
137 on prednisolone (mean daily dose 8 mg or 0.3 mg/kg).  
5.4.1 Drug survival with first-line anti-TNF agents 
During 48-month follow-up, the proportion of patients continuing with etanercept or 
infliximab (Table 11) as the first anti-TNF therapy was comparable in nonadjusted model 
(p=0.194, Figure 10 A) as well as in gender- and disease activity adjusted models 
(p=0.092 and p=0.262, respectively). In this analysis, withdrawal from the anti-TNF agent 
due to an inactive disease was not considered as treatment discontinuation. 
Drug survival with etanercept or infliximab according to JIA subtypes at 24 and 48 
months was 92% and 92% in patients with oligoarthritis, 91% and 78% in ERA, 75% and 
65% in extended oligoarthritis, 65% and 52% in seropositive polyarthritis, 62% and 47% in 
seronegative polyarthritis, and 54% and 24% in sJIA, respectively. In remaining subtypes, 
cases were too few for meaningful statistical comparisons. Drug survival between 
etanercept and infliximab was comparable in patients with seronegative polyarthritis 
(p=0.080), seropositive polyarthritis (p=0.578), ERA (p=0.548), and sJIA (p=0.433). 
Infliximab was discontinued more often in patients with extended oligoarthritis (p=0.019).  
First-line anti-TNF therapy was discontinued in 43% of patients taking etanercept and 
in 59% of those taking infliximab: in 7 (7%) and 23 (22%) due to AEs, in 29 (28%) and 21 
(20%) due to inefficacy, and in 10 (10%) and 17 (16%) due to inactive disease. 
Table 11 Drug survival with first-line or second-line anti-TNF therapy in 209 JIA patients. 
The proportion (%) of patients on therapy with 95% CIs is depicted at each time-point. 
Etanercept Infliximab Adalimumab Drug survival 
%  (95% CI) %  (95% CI) %  (95% CI) 
First-line therapy    
   12 months   83  (76 - 90) 80  (72 - 87)  
   24 months 68  (59 - 78) 68  (58 - 77)  
   36 months 64  (54 - 74) 53  (42 - 64)  
   48 months 61  (50 - 71) 48  (36 - 59)  
   60 months 53  (41 - 65) 45  (33 - 57)  
Second-line therapy    
   6 months 84  (70 - 98) 58  (39 - 76) 73  (51 - 96) 
   12 months 60  (41 - 79) 58  (39 - 76) 66  (42 - 90) 
   24 months 48  (26 - 70) 32  (14 - 50)  
   36 months 38  (14 - 65) 26  (7 - 44)  
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Figure 10 Drug survival (%) with first-line anti-TNF agents etanercept or infliximab in JIA 
patients. Treatment discontinuation during a 48-month follow-up due to all reasons 
except inactive disease (A) and due to adverse events (B). Modified and reprinted with 
kind permission of Annals of Rheumatic Diseases (Tynjälä et al. In press). 
Treatment discontinuation due to AEs, most commonly (93%) side-effects, occurred more 
frequently with infliximab than etanercept (Figure 10 B, p=0.002), also in the gender- and 
disease activity-adjusted models (p=0.001 and p=0.002). One patient on etanercept and one 
on infliximab discontinued the therapy due to fear of injections. 
Treatment discontinuation due to inefficacy was comparable between etanercept and 
infliximab in nonadjusted (Figure 11 C, p=0.445), as well as in gender- and disease 
activity-adjusted models (p=0.600 and p=0.350). 
Discontinuation rates due to inactive disease or remission seemed to be higher during 
infliximab than during etanercept therapy, but this difference was not significant in 
nonadjusted (Figure 11 D, p=0.068), gender-adjusted (p=0.059), or disease activity-
adjusted (p=0.092) models. 
Figure 11  Treatment discontinuation (%) due to inefficacy (C) or inactive disease (D) during a 
48-month follow-up in JIA patients receiving etanercept or infliximab. Modified and 
reprinted with kind permission of Annals of Rheumatic Diseases (Tynjälä et al. In 
press). 
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Predictors of discontinuation of first-line agents 
The risk for discontinuation due to AEs was higher in those taking infliximab rather than 
etanercept, and in girls compared with boys (Table 12). In addition, HLA-B27-positive 
patients had an 81% smaller risk of discontinuing anti-TNF agent due to AEs. When 64 
males, 38 of which were on infliximab were analyzed independently from females, 
discontinuation rates due to AEs between infliximab and etanercept treatment groups were 
not different (p=0.638 in logrank test). The only predictor of anti-TNF discontinuation due 
to inactive disease was duration of JIA; a short duration of JIA at anti-TNF initiation 
predicted treatment discontinuation due to inactive disease or remission.  
Infliximab was discontinued due to inactive disease in 17 patients receiving a mean 
dose of 3.6 (range 2.6-5.8) mg/kg and with a mean infusion interval of 9.3 (range 8-12) 
weeks. By contrast, 22 patients discontinued infliximab due to infusion reactions at a mean 
time of 9.6 (range 0.5-35) months from anti-TNF initiation; these patients received a mean 
dose of 3.1 (range 2.2-5.0) mg/kg and had a mean infusion interval of 6.2 (range 4-8) 
weeks. Compared with the 17 patients with inactive disease, these 22 patients received a 
similar dose (p=0.147), but had a shorter dose interval (p=0.001).  
In 65 patients on infliximab as either first- or second-line therapy and without 
hypersensitivity reactions, the mean infusion interval was 7.3 (range 4-12) weeks with a 
mean dose of 3.9 (range 1.9-11.1) mg/kg. The difference between doses of patients with or 
without infusion reactions was 0.8 mg/kg [(95% CI 0.2 to 1.0), p=0.025]. No significant 
predictors of infusion reactions were found. 
Table 12 Predictors of discontinuation based on Cox regression and hazard ratios (HRs) 
during first-line treatment with infliximab and etanercept in 209 JIA patients. 
Predictors of discontinuation HR 95% CI p 
Due to all reasons except inactive disease  
Female gender 2.8 1.3 - 5.8 0.006 
Systemic JIA 7.8 1.7 - 34.9 0.007 
Infliximab therapy 2.0 1.2 - 3.3 0.004 
Due to inefficacy only    
Systemic JIA 4.2 1.3 - 14.1 0.020 
Seronegative polyarthritis  2.2 1.0 - 4.8 0.048 
Due to AEs only    
Infliximab therapy 4.6 1.8 - 11.8 0.002 
Negative HLA-B27  5.2 1.5 - 18.5 0.009 
Female gender 5.4 1.1 - 26.9 0.039 
Due to inactive disease only     
Duration of JIA  0.77 0.64 - 0.94 0.008 
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Figure 12 Drug treatment survival (%) during the first (etanercept and infliximab combined, 
solid line) and second course (dashed lines) of biologic agents in 73 JIA patients 
switching from one biologic therapy to another. Reprinted with kind permission of 
Annals of Rheumatic Diseases (Tynjälä et al. In press). 
5.4.2 Switch to second-line anti-TNF agents 
Altogether 73 patients (35%) switched biologic therapy: the majority, 77%, from 
etanercept to infliximab or vice versa, 20% to adalimumab, and 3% to anakinra. Mean 
treatment time was 18 months (95% CI 14 to 22) during the first and 16 months (95% CI 
13 to 20) during the second course of therapy (p=ns). The proportion of females was higher 
(p<0.001) among those who switched therapies (88% of 73) than in nonswitchers (60% of 
136). Drug treatment survival with etanercept, infliximab, or adalimumab as the second 
biologic agent (Table 12) was comparable (p=0.196 in logrank test, Figure 12). In the 
switchers, the discontinuation rate due to AEs or inefficacy during first-line anti-TNFs was 
96% and during second-line biologics 53%, significantly less frequent in McNemar’s test 
(p=0.001).
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Predictors of discontinuation of second-line agents 
The second biologic agent was discontinued in 39 patients (53%): in 13 patients due to 
AEs, in 26 patients due to inefficacy, and in 4 patients due to inactive disease. Systemic 
JIA increased the risk for discontinuation also during second-line anti-TNF therapy (Table 
13).
Table 13 Predictors of discontinuation based on a Cox regression model and hazard ratios 
(HRs) during second-line biologic treatment with etanercept, infliximab, adalimumab, or anakinra 
in 73 JIA patients.  
Predictors for discontinuation HR  95% CI p 
Due to both  inefficacy and AEs  
Systemic JIA 4.5 1.8 - 11.3 0.002 
Failure of first course with etanercept 2.2 1.4 - 4.2 0.019 
Due to inefficacy only    
Systemic JIA 9.4 3.1 - 28.5 <0.001 
Negative ANA 2.8 1.2 - 6.5 0.019 
Due to AEs only    
Failure of first course with etanercept 12.6 2.5 - 64.9 0.002 
Discontinuation of first course due to AEs 6.8 1.6-28.7 0.009 
Restart or switch to third-line agents (V) 
In 15% of 209 patients, the first anti-TNF treatment was restarted after a disease flare 
following earlier treatment discontinuation. Restarted therapy was considered successful if 
patients continued it during follow-up. The success rate was similar in etanercept and 
infliximab: 9/19 (47%) and 8/12 (67%), respectively (p=0.120).  
After failure with the second biologic agent, 13 patients from the original etanercept 
group and 7 patients from the original infliximab group switched to third-line biologic 
agent. Switch was successful in 6/13 patients (46%) and in 2/7 patients (29%), 
respectively, when the mean follow-up period was 8 (range 1-21) months, exceeding one 
year only in 6 patients (V). 
63
6  DISCUSSION  
During the last decade, TNF modulators have provided a major step forward in the 
treatment of rheumatic disorders. In researcher-initiated studies, the focus has been on the 
evaluation of long-term safety and efficacy in real-life settings. Such studies are important 
with regard to new medicinal preparations and vulnerable patient groups, e.g. children with 
JIA receiving biologic agents. In the present study, attention was directed to long-term 
evaluation of anti-TNF therapies, including analyses of growth, activity of uveitis, ocular 
complications, and treatment survival.   
6.1 Growth during anti-TNF treatment (I) 
6.1.1. Changes in growth velocity  
The analysis of growth in 71 patients with JIA demonstrated a favorable treatment effect 
for etanercept and infliximab. Patients whose growth velocity had slowed down showed 
significant improvement after the initiation of anti-TNF treatment. The potential for catch-
up growth was highest in those with the greatest growth retardation, and the growth rate 
prior to anti-TNF therapy was the strongest predictor of the quantity of change. The effects 
of etanercept and infliximab on growth were comparable. A decelerating growth velocity 
throughout the four-year follow-up was associated with a higher glucocorticoid dose, older 
age at anti-TNF onset, and poorer response to anti-TNF therapy.  
We suggest that the finding of improved growth velocity during anti-TNF therapy is 
due to decreased inflammation and cytokine levels. In JIA, increases in pro-inflammatory 
cytokines TNF?, IL-1?, and IL-6 may have both local and systemic effects on growth,11, 271
and their expression is known to be associated with increased inflammatory activity.198 In 
animal models, Martensson et al.272 showed that TNF? locally suppressed longitudinal 
bone growth, which was only partially reversed by IGF-1. Although the precise etiology of 
the growth retardation in JIA is unknown, pro-inflammatory cytokines have been proposed 
to be directly associated with growth failure.271 In a recent study, in vitro neutralization of 
IGF-1 and pro-inflammatory cytokines by specific antibodies did not improve metatarsal 
growth. The observation suggests that factors other than pro-inflammatory cytokines may 
have an effect on growth, possibly through IGF-1 independent mechanisms.11  
Among clinical studies, both our investigation and two other reports have demonstrated 
that anti-TNF therapies are effective in suppressing inflammation and restoring growth 
velocity.273, 274 In the latter two studies, JIA patients received etanercept, whereas in our 
series patients received both etanercept and infliximab. Schmeling et al.273 observed 
improved linear growth in 7 children with previous growth delay, and more recently 
Vojvodich et al.274 reported growth improvement in 81% of 31 JIA patients receiving 
etanercept. Our results are in line with these studies.  
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The effect of anti-TNF therapy on skeletal maturation remains obscure. The present 
results suggest that a pathological acceleration in skeletal maturation is unlikely, i.e. no 
abnormal advance in bone age was observed. 
During the use of anti-TNF agents, BMI increased excessively in 10% of subjects. The 
exact reason for this is unknown, and to our knowledge, no previous studies in children 
have reported such an increase during treatment with anti-TNF agents. TNF? has been 
suggested to be involved in body weight homeostasis, which may therefore be affected by 
TNF? targeted therapy. During the course of rheumatic diseases and different treatment 
strategies, obesity and lipid metabolism remain intriguing research subjects, which have 
seldom been explored in children. As a functional precaution to avoid obesity, JIA patients 
achieving inactive disease should be encouraged to exercise at least as much as their 
healthy peers. 
6.1.2. Impact of corticosteroids and treatment response on growth 
One reason for growth retardation in JIA is corticosteroids.6, 7 The present results are 
consistent with this finding. We observed that the four-year cumulative dose of oral 
glucocorticoids and intra-articular steroids was an independent variable predicting the 
change in growth velocity during the follow-up. The intake of steroids was directly 
associated with more severe growth disturbance. Yet, in the multivariate regression model, 
glucocorticoids merely had a moderate effect, suggesting that their impact was only one of 
many affecting growth. Glucocorticoids are known to disturb longitudinal growth through 
several mechanisms, by directly affecting the growth plate137 and interfering with the 
GH/IGF-1 axis,138 among others. Based on the present results, anti-TNF therapies resulted 
in decreased glucocorticoid intake, thus minimizing steroid-related side-effects.  
However, it must be noted that all patients did not benefit from anti-TNF therapies. Of 
the 71 patients, 7% were nonresponsive, with improvement of less than 30% in at least one 
of the three disease activity measures (ESR, CRP, number of active joints). In addition, 
poor response to anti-TNF therapy was associated with delayed growth also after anti-TNF 
onset. Although growth velocity increased after initiation of anti-TNF therapy in the 
majority of patients, midparental target height was not achieved during the follow-up. 
Long-term corticosteroid therapy has been shown to reduce final height, and 30% of 
patients have no catch-up growth following disease remission.6, 7, 79
6.2 Activity of uveitis during anti-TNF treatment  
6.2.1 Etanercept and infliximab (II) 
The cohort we followed consisted of 108 JIA patients commencing biologic treatment in 
1999-2001. All patients were refractory to conventional treatment with DMARDs. The 
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first-line anti-TNF agent was typically initiated due to arthritis, and only in 5% due to 
uveitis. This is partly because of previous and present administration of anti-TNF agents in 
uveitis being off-label. Interestingly, the occurrence of uveitis in our refractory JIA cohort 
was 44%, which is much higher than the 20% described in most earlier series.13 Almost 
two-thirds of our patients had seronegative polyarthritis, in which the occurrence of uveitis 
is usually 5-24%.10, 42, 120, 121 During the two-year follow-up, the frequency of long-term 
complications of uveitis seemed to increase despite decreased ocular inflammatory activity. 
This reflects the chronicity and inevitable long-term consequences of childhood uveitis 
regardless of adherence to current treatment. At the initiation of anti-TNF therapy in our 
cohort, uveitis had already persisted for five years in 38% of patients, and for more than a 
decade in 11%.  
The optimal treatment for uveitis is not thoroughly known. Early detection and 
effective treatment form the basis for a better prognosis.12, 123, 124 Early initiation of 
immunomodulators is recommended to avoid the sight-threatening complications of uveitis 
and the side-effects of topical and oral steroids. The most frequently initiated conventional 
immunomodulator, MTX, has been suggested to be effective or even to induce 
remission.22, 186, 188 Less reports exist on the potential benefits of CSA.170, 189 The increasing 
use of anti-TNF therapy in rheumatic diseases has led to studies of the effect of biological 
drugs on uveitis. 
Although studies on uveitis in JIA patients are few and observational, they have been 
rather consistent regarding the effects of etanercept and infliximab. Etanercept has been 
suggested to have minor or no effect on uveitis even in one small RCT,249, 250 whereas only 
positive reports on the efficacy of infliximab have been published.253-256 To date, one 
questionnaire-based survey has reported the outcome of etanercept and infliximab 
treatment in JIA-associated uveitis.260 In other retrospective and smaller patient series, the 
study population has been even more heterogeneous, consisting of patients with 
sarcoidosis, Beçhet disease, JIA, ankylosing spondylitis, RA, or adults with other 
conditions.
To our knowledge, the present uveitis series, with 45 JIA patients and a follow-up of up 
to two years, is in children the largest published report on etanercept and infliximab 
treatment in JIA-associated uveitis. Our retrospective analysis suggests that anti-TNF 
therapies have beneficial effects in JIA patients with uveitis. Infliximab, a monoclonal 
TNF? antibody, seemed to demonstrate a more favorable effect than etanercept, a soluble 
TNF receptor, in controlling ocular inflammation. 
6.2.2 Adalimumab (III) 
During adalimumab therapy, uveitis improved in 35% of patients. Patients with a favorable 
response were younger, had a shorter duration of JIA, and had a lower active joint count at 
baseline. Of note, 95% of the 21 JIA patients in this series had an insufficient response to 
previous second-line agents combined with first-line anti-TNF therapy, indicating that this 
series represented those with a refractory course of uveitis. Based on published reports, 
adalimumab has demonstrated an acceptable safety profile, a low rate of serious AEs, and 
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none of the hypersensitivity reactions found with infliximab.234, 235, 257, 258 Adalimumab, 
thus, is an interesting treatment option in refractory uveitis.   
Although one-third of patients with refractory uveitis improved, we did not observe as 
beneficial an ophthalmologic outcome as reported in the three investigations described 
below. Biester et al.257 documented improvement in 89% of patients, but favorable 
response was based on number of relapses. However, their patients had a shorter duration 
of disease than in our series. Vazquez-Cobian et al.258 showed improved activity in 81% of 
eyes, which is markedly more than the 20% in our series. Their patients were younger, the 
underlying conditions were different, and the definition of improvement was not as 
stringent as in our series. A recent survey lacking detailed ophthalmologic data reported 
that all three patients who had experienced failure with infliximab had a favorable response 
to adalimumab.260 Compared with earlier results, differences in patient characteristics and 
response criteria in our study may explain the lower rate of favorable outcome.  
The majority (90%) of our patients were considered infliximab failures because of 
either inefficacy or side-effects. This is clearly different from the series of Biester et al.,257
where only 28% had experienced failure with infliximab. Infliximab doses of 3-5 mg/kg, 
recommended in the early years, are probably suboptimal for the treatment of uveitis. In a 
recent publication, patients with refractory uveitis were treated successfully with 
infliximab doses of up to 10-20 mg/kg.256 However, no toxicity analyses of high-dose 
infliximab treatment have yet been published, and the high costs of this treatment may 
limit its further use.  
When evaluating the AC cell activity in uveitis, we tested both the recently published 
SUN criteria107 and modified criteria.268, 269 The results between these two methods did not 
differ appreciably, although the proportion of patients without any change in the activity of 
uveitis was higher when assessed by SUN criteria, which is due to the requirement of a 
two-step change in the activity of uveitis. This requirement may diminish the confounding 
effect of spontaneous fluctuation in the number of AC cells on the results. To facilitate the 
comparison of different studies in the future, a consensus on common response criteria is 
needed.
6.2.3 Impact of anti-TNF agents in uveitis (II-III) 
Anti-TNF drugs offer an exciting treatment option for refractory uveitis, but their 
mechanism of action in the eye is not fully understood, and the efficacy of monoclonal 
TNF? antibodies has not yet been proven by any RCT. It may be speculated that the 
clinical perception of better efficacy of TNF? antibodies in uveitis in JIA could be 
explained at least partly by different binding characteristics. Whereas soluble TNF receptor 
etanercept binds primarily to soluble TNF, both infliximab and adalimumab bind to soluble 
and membrane-bound TNF?. Infliximab is also capable of deleting T-cells producing 
TNF?. Differences in binding may lead to differing effects on complement activation and 
apoptosis, which may in turn have an impact on uveitis.
Another observation based on the present results is the high rate of complications. In 
patients receiving adalimumab, the mean duration of uveitis was nine years. Although 
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BCVA was not decreased at the end of the follow-up, up to 70% of patients had cataract, 
55% glaucoma, 40% band keratopathy, and 40% macular edema, when anti-TNF agents 
had been initiated only for a mean of two years earlier. The high rate of complications, 
despite of ongoing second-line and third-line therapy, underlines the importance of early 
effective treatment of anterior uveitis.  
6.3 Anti-TNF agents in arthritis (III) 
6.3.1 Etanercept and infliximab (V)  
In JIA, an impressive efficacy of etanercept and infliximab has been demonstrated in a few 
prospective trials; in etanercept, a sustained efficacy has been shown for up to 8 years,227, 
228
 and in infliximab, an efficacy for up to one year. 223, 231 In the present study, we reported 
changes in disease activity parameters, i.e. ESR, CRP, and active joint count. Due to the 
retrospective setting and nonrandomized treatment groups, we were unable to perform full 
efficacy analysis or to compare the efficacy of etanercept and infliximab treatment. 
However, the impact of etanercept and infliximab in our series, especially in patients with 
elevated active joint count at baseline, was in line with that of prospective RCTs or open-
label studies, with a markedly decreased active joint count at the end of follow-up and no 
apparent differences between etanercept and infliximab treatment groups (V).  
6.3.2. Efficacy of adalimumab (III) 
In RA, long-term data on adalimumab have demonstrated sustained efficacy and an 
acceptable safety profile, both efficacy and safety being comparable with other TNF 
antagonists.234 No prospective studies on the efficacy of adalimumab in JIA patients have 
yet been published. The findings of a two-year efficacy trial in JIA were recently reported 
as an abstract, where the ACR Pedi30, 50, and 70 responses were 94%, 93%, and 81%, 
respectively.235 Our study sample was much smaller, the median duration of JIA was 12 
years at the onset of adalimumab, and the long-term response rate was considerably lower 
than in the series of Lovell et al.235 In the retrospective series of Biester et al.,257
adalimumab induced inactive arthritis in 63% of patients, and our findings were more in 
line with this series. The prospective multicenter RCT of Lovell et al.235 consisted of 
selected patient series, whereas the patient cohort in our series represented a real-life 
clinical series. This may at least partly explain the different response rates between the 
studies.
In this series, in the majority of patients, the favorable responses to arthritis and uveitis 
seemed to run different courses. Thus, optimizing a treatment of a child who has at times 
flares in arthritis or in uveitis is remarkably challenging, and requires close collaboration of 
pediatric rheumatologists and ophthalmologists.   
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6.4 Drug survival with anti-TNF agents (IV) 
6.4.1 Drug survival and switch  
In a real-life setting, the four-year treatment survival with anti-TNF agents etanercept and 
infliximab in JIA was comparable. During infliximab therapy, however, the 
discontinuation rate due to AEs, but not due to inefficacy or inactive disease, was higher 
than during etanercept therapy. Although our patient series reflected the heterogeneous 
population of clinical practice, the drug survival rate of first anti-TNF therapy was in line 
with that seen in prospective efficacy studies on etanercept226 and infliximab.223 Compared 
with the prospective series of Ruperto et al., 223 treatment discontinuation due to AEs with 
infliximab in our patient series occurred more often and earlier. Throughout 1999-2004, we 
used the recommended 3 mg/kg doses, which are now known to be associated with 
infusion reactions more frequently than 6 mg/kg doses.223 This may at least partly explain 
the difference in discontinuation rates.  Also the development of anti-TNF drug-specific 
antibodies has been observed, and may partly explain the weaning of therapeutic effect.223
To the best of our knowledge, our study is the first in JIA to evaluate switching 
between anti-TNF therapies. Of patients discontinuing the first anti-TNF agent, 
approximately half were able to continue the second throughout the four-year follow-up. In 
a UK register study, 73% of RA patients switching biologic agents continued the second 
anti-TNF agent for a mean of six months,275 which is consistent with our findings. 
Although AEs in our study were different from those in the UK series, discontinuation of 
the first anti-TNF agent due to AEs was related to discontinuation of the second agent due 
to AEs in both series. Inefficacy of the first anti-TNF agent did not seem to predict 
inefficacy of the second anti-TNF agent in JIA, while in RA discontinuation rates due to 
inefficacy during the first and second course of anti-TNFs were associated.275 This 
suggests that in JIA switching from one anti-TNF agent to another can be considered a 
reasonable therapeutic option. However, analysis of larger series in those JIA patients 
switching biologic agents is still needed.  
In adults, some preliminary evidence has been reported on the benefits of early 
aggressive anti-TNF treatment to induce remission. In the BeSt study, the combination of 
initial infliximab and MTX led to a higher remission rate and more often discontinuation of 
all anti-rheumatic drugs than conventional treatment strategies.193 Interestingly, in our 
study, commencement of anti-TNF treatment early in the course of JIA was associated 
with discontinuation of anti-TNFs due to inactive disease, which suggests indirectly that 
early anti-TNF treatment may induce clinical remission. 
6.4.2 Patient outcome in JIA subtypes and subgroups  
Baseline characteristics of those receiving etanercept and infliximab as a first-line TNF 
blocker were markedly different. Pediatric rheumatologists seemed to initiate infliximab 
more often to somewhat older children and to those with uveitis. By contrast, almost all 
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patients with sJIA received etanercept. Several explanations for this selection bias are 
possible. First of all, the limited supply of etanercept at the beginning of this millennium 
led in Finland to off-label pediatric use of infliximab for several years before the 
publication of the first RCT in JIA.223 Without any pediatric safety and toxicity studies 
available, infliximab was administered off-label, preferably to older children. Moreover, 
based on initial clinical observations, infliximab and adalimumab have been preferred in 
JIA patients with refractory uveitis, although no randomized studies have confirmed the 
better efficacy of monoclonal TNF? antibodies in uveitis compared with etanercept. 
Of the JIA subtypes, treatment termination due to inefficacy during both the first and 
the second anti-TNF therapies was strongly associated with systemic onset JIA. This is 
hardly surprising because the response of biologic therapy in JIA seems to be subtype-
specific.225, 228 In sJIA, a few studies have investigated the efficacy of etanercept, but little 
is known about the efficacy of other anti-TNF agents. Kimura et al.276 reported that of their 
45 sJIA patients more than 50% had a poor or fair response to etanercept. Other studies 
have reported discontinuation rates of etanercept of up to 42%.225, 228 In our cohort, this 
was even higher; during the first course of anti-TNFs, the discontinuation rate in patients 
with sJIA was 69% and during the second course 100%. In our study, a few patients 
receiving IL-1 receptor antagonist anakinra as a second-line biologic agent were observed 
to have poor treatment survival. In sJIA, some promising results on the efficacy of 
anakinra treatment exist,237 although the efficacy in juvenile patients is probably not as 
good as in adults.31
In patients with ERA, 56% of whom were HLA-B27-positive, the discontinuation rate 
was quite low, only 14%. This concurs with previous findings of 19% in 26 patients with 
ERA in the German etanercept registry,228 with sustained efficacy of etanercept of over 
two years in 8 ERA patients (7 HLA-B27-positive) in the study of Henrickson and Reiff,229
and with sustained efficacy of anti-TNF therapy of over one year in 10 HLA-B27-positive 
patients with JSPA.230 In our cohort, HLA-B27 positivity and male gender, but not ERA, 
were protective factors against treatment discontinuation due to AEs. This may in part be 
explained by the higher proportion of females among the poorer-responding and HLA-
B27-negative patients with sJIA or highly active polyarthritis, but may also be an 
independent factor, thus warranting further investigation. In RA patients receiving biologic 
agents, females are less likely to achieve remission.275 In JIA, female gender has been 
demonstrated to be a predictor of disability61 and continued disease activity.57
6.5 Limitations of the study (I-IV) 
Our series represent a real-life cohort of anti-TNF users, with the limitations being those of 
many retrospective and register studies. However, all patients starting anti-TNF therapy 
were included. Moreover, due to continuous disease activity in these refractory patients, 
none was lost to follow-up, and long-term treatment took place regularly in the same 
tertiary pediatric rheumatology clinics. In this way, we were able to collect a large amount 
of information on a rare patient group. 
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In the study of growth (I), neither pubertal staging nor target height was assessed for all 
patients. Instead, to estimate the timing of the pubertal growth spurt, we used bone age 
measurements. Although our study was retrospective, this made analysis of growth more 
precise.
In the studies on uveitis, at least during 1999-2001, improvement of uveitis during 
infliximab therapy was not yet widely recognized. Thus, in the early years of anti-TNF 
treatment, selection bias can be considered quite low (II) compared with the later phases of 
the study (III). However, in our first study on uveitis (II), patients were not randomized 
into treatment groups, and the conventional therapy for all patients was also not similar. In 
the future, RCTs will be needed to reveal whether a true clinically and statistically 
significant difference exists between the treatments. Additionally, when we started our data 
collection, no international consensus on the improvement criteria of uveitis existed. Only 
after submitting our first manuscript on uveitis (II) were the SUN criteria published. In our 
second study of uveitis, we therefore evaluated the results with two methods (III). 
In our patient series, the high proportion of patients receiving monoclonal TNF?
antibodies with JIA-associated uveitis may have affected drug survival and discontinuation 
rates (IV). Moreover, due to the retrospective setting, the six core measures of the ACR 
Pediatric criteria were unavailable for all patients, and thus, we were unable to perform a 
complete efficacy analysis (IV, V).  
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7  CONCLUSIONS  
In JIA, normal growth and development are essential aims of treatment, which cannot be 
achieved without a good control of disease activity. Growth retardation and reduced final 
height are among the disabling complications of especially polyarticular and systemic JIA. 
For these patients, the recently introduced anti-TNF therapies and other biologic disease 
modifiers are the most promising treatment options available. In most cases, combined 
with conventional therapy, biologic agents can sufficiently control refractory rheumatic 
inflammation and minimize steroid-related side-effects. Thus, the goal of current treatment 
strategy, remission, may be reached. Patients with inactive disease are the most likely to 
avoid the long-term consequences of JIA.  
For JIA-associated anterior uveitis, no optimal therapy exists at the moment. In non-
responsive cases, treatment should be intensified with early immunosuppressive drugs, 
which fail to control AC inflammation of the eye in 20% of patients. The longer the disease 
is uncontrolled, the poorer the outcome will be. Although we still lack more specific 
therapy, both in vitro and in vivo studies with anti-TNF agents and other biologic therapies 
provide a promising approach in uveitis. Unfortunately, the optimal timing of second- and 
third-line therapy with conventional and/or anti-TNF agents in is not yet well known. 
In our JIA series (I), anti-TNF therapy with etanercept or infliximab was highly 
effective in controlling the rheumatic inflammation. In most children refractory to 
conventional disease-modifying drugs and with compromised growth, anti-TNF agents 
were effective in restoring normal growth and even in inducing catch-up growth. The more 
growth velocity had been impaired, the higher was the potential to catch-up growth. 
Reduced inflammation was one of multiple factors positively affecting growth, as was also 
reduced intake of corticosteroids.   
In our retrospective case series (II, III), JIA-associated uveitis improved in one-third of 
patients receiving anti-TNF agents. Treatment especially with monoclonal TNF?
antibodies infliximab and adalimumab seemed to be profitable, whereas treatment with the 
soluble TNF receptor etanercept was less beneficial. Our current sequence of treatment in 
refractory uveitis is MTX combined with topical steroids and in non-responsive cases, 
infliximab. The present results suggest that adalimumab may be an equivalent treatment 
option to infliximab, and may be useful even in infliximab failures. However, prospective 
randomized studies will be needed to evaluate efficacy and safety of biological drugs in 
JIA-associated uveitis in a stringent scientific fashion. 
Results of the long-term monitoring of JIA patients suggested that the overall treatment 
survival of etanercept and infliximab as the first-line biologics was comparable (IV), 
although infliximab was discontinued more often due to AEs. Among the subtypes of JIA, 
risk for treatment discontinuation was highest in systemic arthritis. Female gender was an 
independent risk factor for treatment discontinuation. Even as second-line anti-TNF agents, 
treatment survival with etanercept, infliximab, or adalimumab was satisfactory. Thus, a 
switch to another anti-TNF agent for non-systemic JIA patients who experience failure 
with the first anti-TNF agent can be recommended. In the future, other biologic compounds 
may provide therapeutic options for JIA patients refractory to anti-TNF agents. 
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